1. Field of the Invention
The present invention generally relates to medical devices and methods, and more particularly relates to the treatment of valve insufficiency, such as mitral insufficiency, also referred to as mitral regurgitation. The use of prosthetic valves delivered by traditional surgical implantation methods, or by a less invasive percutaneous catheter or by minimally invasive transapical methods are one possible treatment for valvar insufficiency (also referred to as regurgitation).
The heart of vertebrate animals is divided into four chambers, and is equipped with four valves (the mitral, aortic, pulmonary and tricuspid valves) that ensure that blood pumped by the heart flows in a forward direction through the cardiovascular system. The mitral valve of a healthy heart prevents the backflow of blood from the left ventricle into the left atrium of the heart, and comprises two flexible leaflets (anterior and posterior) that close when the left ventricle contracts. The leaflets are attached to a fibrous annulus, and their free edges are tethered by subvalvular chordae tendineae to papillary muscles in the left ventricle to prevent them from prolapsing into the left atrium during the contraction of the left ventricle.
Various cardiac diseases or degenerative changes may cause dysfunction in any of these portions of the mitral valve apparatus, causing the mitral valve to become abnormally narrowed or dilated, or to allow blood to leak (i.e. regurgitate) from the left ventricle back into the left atrium. Any such impairments compromise cardiac sufficiency, and can be debilitating or life threatening.
Numerous surgical methods and devices have accordingly been developed to treat mitral valve dysfunction, including open-heart surgical techniques for replacing, repairing or re-shaping the native mitral valve apparatus, and the surgical implantation of various prosthetic devices such as annuloplasty rings to modify the anatomy of the native mitral valve. More recently, less invasive transcatheter techniques for the delivery of replacement mitral valve assemblies have been developed. In such techniques, a prosthetic valve is generally mounted in a crimped state on the end of a flexible catheter and advanced through a blood vessel or the body of the patient until the valve reaches the implantation site. The prosthetic valve is then expanded to its functional size at the site of the defective native valve.
While these devices and methods are promising treatments for valvar insufficiency, they can be difficult to deliver and anchor, expensive to manufacture, or may not be indicated for all patients. Some of these prosthetic valves having anchoring mechanisms that secure the valve to various portions of the valve anatomy. For example, some the valves are anchored to the atrial floor, the valve annulus, a ventricular wall, or to the valve leaflets. However, in some situations, depending on anatomy, skill of the physician, as well as other factors, the prosthetic valve may not always be successfully anchored. For example, in the case of a prosthetic mitral valve with anchors for securing the valve to the native anterior and posterior leaflets, if the anchor(s) do not successfully engage the posterior leaflet, the prosthetic valve may be pushed upward toward the atrium during ventricular contraction due to the force of the blood. This may result in an improperly positioned valve which can prevent the valve from properly functioning. Therefore, it would be desirable to provide improved devices and methods for the treatment of valvar insufficiency such as mitral insufficiency. Such devices preferably have alternative or improved anchoring mechanisms to more securely anchor the prosthesis to the valve structure. At least some of these objectives will be met by the devices and methods disclosed below.
2. Description of the Background Art
By way of example, PCT international patent number PCT/US2008/054410 (published as PCT international publication No. WO2008/103722), the disclosure of which is hereby incorporated by reference, describes a transcatheter mitral valve prosthesis that comprises a resilient ring, a plurality of leaflet membranes mounted with respect to the ring so as to permit blood flow therethrough in one direction, and a plurality of tissue-engaging positioning elements movably mounted with respect to the ring and dimensioned to grip the anatomical structure of the heart valve annulus, heart valve leaflets, and/or heart wall. Each of the positioning elements defines respective proximal, intermediate, and distal tissue engaging regions cooperatively configured and dimensioned to simultaneously engage separate corresponding areas of the tissue of an anatomical structure, and may include respective first, second, and third elongate tissue-piercing elements. The valve prosthesis may also include a skirt mounted with respect to the resilient ring for sealing a periphery of the valve prosthesis against a reverse flow of blood around the valve prosthesis.
PCT international patent number PCT/US2009/041754 (published as PCT international publication No. WO2009/134701), the disclosure of which is hereby incorporated by reference, describes a prosthetic mitral valve assembly that comprises an anchor or outer support frame with a flared upper end and a tapered portion to fit the contours of the native mitral valve, and a tissue-based one-way valve mounted therein. The assembly is adapted to expand radially outwardly and into contact with the native heart tissue to create a pressure fit, and further includes tension members anchoring the leaflets of the valve assembly to a suitable location on the heart to function as prosthetic chordae tendineae.
Also known are prosthetic mitral valve assemblies that utilize a claw structure for attachment of the prosthesis to the heart (see, for example, U.S. Patent Publication No. US2007/0016286 to Hermann et al., the disclosure of which is hereby incorporated by reference), as are prosthetic mitral valve assemblies that rely on the application of axial rather than radial clamping forces to facilitate the self-positioning and self-anchoring of the prosthesis with respect to the native anatomical structure.
Another method which has been proposed as a treatment of mitral valve regurgitation is the surgical bow tie method, which recently has been adapted into a minimally invasive catheter based treatment where an implant is used to clip the valve leaflets together. This procedure is more fully disclosed in the scientific and patent literature, such as in U.S. Pat. No. 6,629,534 to St. Goar et al., the entire contents of which are incorporated herein by reference.
Other relevant publications include U.S. Patent Publication No. 2011/0015731 to Carpentier et al. and WO2011/137531 to Lane et al. While some of these devices and methods are promising, there still is a need for improved devices and methods that will further allow more accurate positioning of a prosthetic valve and that will also more securely anchor the valve in place. At least some of these objectives will be met by the exemplary embodiments disclosed herein.
The present invention generally relates to medical devices and methods, and more particularly prosthetic valves used to treat mitral regurgitation. While the present disclosure focuses on the use of a prosthetic valve for treating mitral regurgitation, this is not intended to be limiting. The prosthetic valves disclosed herein may also be used to treat other body valves including other heart valves or venous valves. Exemplary heart valves include the aortic valve, the tricuspid valve, or the pulmonary valve.
In a first aspect of the present invention, a prosthetic valve for implanting in a native valve of a patient comprises a self-expanding frame having a first end, a second end opposite the first end, an atrial region near the second end, a ventricular region near the first end, an anterior portion, and a posterior portion. The self-expanding frame has an expanded configuration and a collapsed configuration. The expanded configuration is adapted to engage tissue at a treatment site, and the collapsed configuration is adapted to be delivered to the treatment site. The expandable frame comprises a self-expanding atrial skirt disposed in the atrial region, a self-expanding ventricular skirt disposed in the ventricular region, a self-expanding annular region disposed between the atrial region and the ventricular region, a first self-expanding anterior tab disposed on the anterior portion of the self-expanding frame in the ventricular region, and a self-expanding foot coupled to the ventricular region. The foot is disposed in the posterior portion and extends radially outward from the self-expanding frame and has an outer surface for engaging the tissue thereby facilitating anchoring of the prosthetic valve and minimizing or preventing rotation of the prosthetic valve. Preferably the foot prevents or minimizes rotation of the prosthesis upstream into or toward the left atrium, although it may help anchor the prosthesis and prevent or minimize pivoting in a direction that depends on the anatomy being treated.
The prosthetic valve may be a prosthetic mitral valve. The atrial skirt may have a collapsed configuration and an expanded configuration. The collapsed configuration may be adapted for delivery to the treatment site, and the expanded configuration may be radially expanded relative to the collapsed configuration and adapted to lie over a superior surface of the patient's native valve, thereby anchoring the atrial skirt against a superior portion of the native valve. The atrial skirt may comprise a plurality of axially oriented struts connected together with a connector element thereby forming a series of peaks and valleys. After self-expansion of the atrial skirt, the atrial skirt may form a flanged region adjacent the second end of the self-expanding frame. The atrial skirt may have an asymmetrically D-shaped cross-section having a substantially flat anterior portion, and a cylindrically shaped posterior portion after self-expansion. The prosthetic valve may further comprise an alignment element coupled to an anterior portion of the atrial skirt. The alignment element may be adapted to be aligned with an aortic root of a patient's heart and may be adapted to be disposed between two fibrous trigones of an anterior leaflet of the patient's mitral valve.
At least a portion of the ventricular skirt may be covered with tissue or a synthetic material. After self-expanding, the ventricular skirt may comprise an asymmetrically D-shaped cross-section having a substantially flat anterior portion, and a cylindrically shaped posterior portion. The ventricular skirt may have a collapsed configuration and an expanded configuration. The collapsed configuration may be adapted for delivery to the treatment site, and the expanded configuration may be radially expanded relative to the collapsed configuration and may also be adapted to displace native mitral valve leaflets radially outward. The ventricular skirt may further comprise a plurality of barbs coupled thereto. The plurality of barbs may be adapted to anchor the ventricular skirt into the tissue. The ventricular skirt may comprise a plurality of struts connected together with a connector element thereby forming a series of peaks and valleys. Any of the struts in the prosthetic valve may have one or more suture holes extending through the strut and sized to receive a suture.
The annular region may have a collapsed configuration and an expanded configuration. The collapsed configuration may be adapted for delivery to the treatment site. The expanded configuration may be radially expanded relative to the collapsed configuration and may be adapted to conform with and may be adapted to engage an annulus of the native valve. After self-expanding, the annular region may have an asymmetrically D-shaped cross-section having a substantially flat anterior portion, and may also have a cylindrically shaped posterior portion. The annular region may comprise a plurality of axially oriented struts connected together with a connector element, and that may form a series of peaks and valleys. One or more of the plurality of axially oriented struts may comprise one or more suture holes extending through the strut, and the holes may be sized to receive a suture.
The first anterior tab may have a tip portion that is adapted to engage a first fibrous trigone on a first side of an anterior leaflet of the patient's mitral valve. The first anterior tab may be adapted to capture the anterior leaflet and adjacent chordae tendineae between the first anterior tab and an outer anterior surface of the ventricular skirt. The prosthetic valve may further comprise a second self-expanding anterior tab disposed on the anterior portion of the self-expanding frame in the ventricular region. The second anterior tab may have a tip portion that is adapted to engage a second fibrous trigone on a second side of the anterior leaflet of the patient's mitral valve opposite the first side of the anterior leaflet. The second anterior tab may be adapted to capture the anterior leaflet and adjacent chordae tendineae between the second anterior tab and the outer surface of the ventricular skirt.
The prosthetic valve may further comprise a covering disposed over the first or the second anterior tabs. The covering increases contact surface area of the respective first or second anterior tab with the heart or other treatment tissue. The covering may comprise a fabric material disposed over a polymer tab that is coupled to the first or the second anterior tab.
Rotation of the posterior portion of the prosthetic valve may be minimized or prevented relative to the anterior portion of the prosthetic valve with the foot. Rotation may be minimized or prevented in an upstream direction toward the left atrium of the patient's heart. The foot may be covered with a synthetic material or with tissue. The foot may comprise a wedge shaped element extending radially outward from the self-expanding frame. The foot may comprise a central elongate element and a cover. The cover may be disposed over the central elongate element and the cover may be coupled to a strut on either side thereof. The central elongate element may comprise a pair of struts coupled together to form a U-shape or a V-shape. The foot may form a vestibule on the posterior portion of the prosthetic valve. The foot may comprise barbs, texturing or other surface features for anchoring the foot to tissue.
The prosthetic valve may further comprise a plurality of prosthetic valve leaflets. Each of the leaflets may have a first end and a free end, and the first end may be coupled with the self-expanding frame and the free end may be opposite of the first end. The prosthetic valve leaflets may have an open configuration in which the free ends of the prosthetic valve leaflets are disposed away from one another to allow antegrade blood flow therepast, and a closed configuration in which the free ends of the prosthetic valve leaflets engage one another and substantially prevent retrograde blood flow therepast. The plurality of prosthetic valve leaflets may form a tricuspid valve. At least a portion of one or more prosthetic valve leaflets may comprise tissue or a synthetic material. One or more of the prosthetic valve leaflets may comprise a commissure post having a commissure tab. The commissure tab may be adapted to be releasably engaged with a delivery device. The prosthetic valve may carry a therapeutic agent that is adapted to being eluted therefrom. The prosthetic valve may further comprise a posterior ventricular anchoring tab disposed on a posterior portion of the self-expanding frame. The posterior ventricular anchor tab may be anchored over a posterior leaflet of the patient's mitral valve such that the posterior ventricular anchoring tab is seated between the posterior leaflet and a ventricular wall of the patient's heart. The posterior ventricular anchoring tab may have barbs, texturing or other surface features disposed thereon, and that are adapted to engage tissue and anchor the posterior ventricular tab to the tissue.
In another aspect of the present invention, a method for anchoring a prosthetic valve in a native valve of a patient's heart comprises providing a prosthetic valve and advancing the prosthetic valve in a collapsed configuration to the native valve. The prosthetic valve may comprise an expandable frame having a first end, a second end opposite the first end, a first anterior tab on an anterior portion of the expandable frame adjacent the first end, a foot on a posterior portion of the expandable frame adjacent the first end, an atrial skirt adjacent the second end of the expandable frame, and an annular region disposed between the first and second ends. The prosthetic valve also has an expanded configuration for engaging the native valve. The method also includes expanding the first anterior tab, and expanding the foot. The first anterior tab is expanded radially outward such that a tip of the first anterior tab engages a first fibrous trigone on a first side of an anterior leaflet of the native valve. The anterior leaflet may then be disposed between the first anterior tab and an outer surface of the ventricular skirt. The foot is expanded radially outward such that the foot engages a posterior portion of the native valve thereby anchoring the prosthetic valve to a posterior portion of the native valve and preventing or minimizing rotation of the prosthetic valve upstream into or toward the left atrium.
Providing the prosthetic valve may further comprise providing a delivery device for delivering the prosthetic valve to the native valve, and the prosthetic valve may be releasably coupled to the delivery device.
Advancing the prosthetic valve may comprise transapically delivering the prosthetic valve from a region outside of the patient to the patient's heart. Advancing the prosthetic valve may comprise transseptally delivering the prosthetic valve from the right atrium to the left atrium of the patient's heart. Advancing the prosthetic valve may comprise positioning the prosthetic valve across the patient's mitral valve so that the second end is superior to the mitral valve and the first end is inferior to the mitral valve.
Expanding the first anterior tab may comprise retracting a constraining sheath therefrom and allowing the first anterior tab to self-expand radially outward. The prosthetic valve may further comprise a second anterior tab on the anterior portion of the expandable frame, and the method may further comprise expanding the second anterior tab radially outward such that a tip portion of the second anterior tab engages a second fibrous trigone on a second side of the anterior leaflet opposite the first side of the anterior leaflet. The second anterior tab may expand radially outward concurrently with expansion of the first anterior tab. Expanding the second anterior tab may comprise retracting a constraining sheath from the second anterior tab so that the second anterior tab is free to self-expand radially outward. The first and second anterior tabs may both self-expand when a single constraining sheath is retracted.
Expanding the foot may form a vestibule adjacent the first end of the prosthetic valve, and may increase the size of the first end of the prosthetic valve so that it cannot pass through the native valve. Expanding the foot may comprise retracting a constraint therefrom so that the foot self-expands radially outward. The posterior chordae tendineae may engage the expanded foot. The foot may comprise barbs, texturing, or other surface features. Expanding the foot may engage the barbs, texturing or other surface features with tissue thereby anchoring the foot with the tissue.
The method may also comprise expanding the ventricular skirt radially outward into engagement with the anterior and posterior leaflets of the native valve. The anterior chordae tendineae may be disposed between the first anterior tab and the outer surface of the ventricular skirt. Expanding the ventricular skirt may comprise retracting a constraining sheath from the ventricular skirt so that the ventricular skirt is free to self-expand radially outward. The ventricular skirt may comprise a plurality of barbs, and expanding the ventricular skirt may comprise anchoring the plurality of barbs into heart tissue. The prosthetic valve may further comprise a plurality of commissures, and expanding the ventricular skirt may displace the anterior and posterior leaflets of the native valve radially outward thereby preventing interference between the commissures and the leaflets. Expanding the ventricular skirt may displace the anterior and posterior leaflets of the native valve radially outward without contacting an inner wall of the left ventricle, and without obstructing a left ventricular outflow tract. Radially expanding the ventricular skirt may expand the ventricular skirt asymmetrically such that an anterior portion of the ventricular skirt is substantially flat, and a posterior portion of the ventricular skirt is cylindrically shaped.
The method may also include expanding the annular region radially outward so as to engage an annulus of the native valve. Expanding the annular region may comprise retracting a constraining sheath therefrom so that the annular region is free to self-expand radially outward. Expanding the annular region may comprise asymmetrically expanding the annular region such that an anterior portion of the annular region is substantially flat, and a posterior portion of the annular region is cylindrically shaped.
The native valve may be a mitral valve, and the method may further comprise reducing or eliminating mitral regurgitation. The prosthetic valve may carry a therapeutic agent, and the method may further comprise eluting the therapeutic agent from the prosthetic valve into adjacent tissue.
The prosthetic valve may comprise an alignment element, the method may further comprise aligning the alignment element with an aortic root and disposing the alignment element between the first and second fibrous trigones. Aligning the alignment element may comprise rotating the prosthetic valve.
The prosthetic valve may further comprise a plurality of commissures with a covering disposed thereover whereby a plurality of prosthetic valve leaflets are formed. The method may further comprise releasing the plurality of prosthetic valve leaflets from a delivery catheter. The plurality of prosthetic valve leaflets may form a tricuspid valve that has an open configuration and a closed configuration. The plurality of prosthetic valve leaflets are disposed away from one another in the open configuration thereby permitting antegrade blood flow therethrough, and the plurality of prosthetic valve leaflets engage one another in the closed configuration thereby substantially preventing retrograde blood flow therethrough. The prosthetic valve may further comprise an atrial skirt adjacent the second end, and the method may further comprise expanding the atrial skirt radially outward so as to lie over a superior surface of the native valve, and engaging the atrial skirt against the superior surface of the native valve. Expanding the atrial skirt may comprise retracting a constraining sheath from the atrial skirt so that the atrial skirt is free to self-expand radially outward. The method may also comprise moving the prosthetic valve upstream or downstream relative to the native valve to ensure that the atrial skirt engages the superior surface of the native valve. Engaging the atrial skirt against the superior surface may seal the atrial skirt against the superior surface of the native valve to prevent or substantially prevent blood flow therebetween. The prosthetic valve may further comprise a posterior ventricular anchoring tab that is disposed on a posterior portion of the self-expanding frame. The method may further comprise anchoring the posterior ventricular anchoring tab over a posterior leaflet of the patient's mitral valve such that the posterior ventricular anchoring tab is seated between the posterior leaflet and a ventricular wall of the patient. The posterior ventricular tab may comprise barbs, texturing, or other surface features. Anchoring the posterior ventricular tab may comprise engaging the barbs, texturing or other surface features with tissue.
These and other embodiments are described in further detail in the following description related to the appended drawing figures.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
Specific embodiments of the disclosed device, delivery system, and method will now be described with reference to the drawings. Nothing in this detailed description is intended to imply that any particular component, feature, or step is essential to the invention.
Cardiac Anatomy. The left ventricle LV of a normal heart H in systole is illustrated in
Referring now to
Regurgitation also occurs in the patients suffering from cardiomyopathy where the heart is dilated and the increased size prevents the valve leaflets LF from meeting properly, as shown in
Mitral valve regurgitation can also occur in patients who have suffered ischemic heart disease where the functioning of the papillary muscles PM is impaired, as illustrated in
While various surgical techniques as well as implantable devices have been proposed and appear to be promising treatments for mitral regurgitation, surgical approaches can require a lengthy recovery period, and implantable devices have varying clinical results. Therefore, there still is a need for improved devices and methods for treating mitral regurgitation. While the embodiments disclosed herein are directed to an implantable prosthetic mitral valve for treating mitral regurgitation, one of skill in the art will appreciate that this is not intended to be limiting, and the device and methods disclosed herein may also be used to treat other cardiac valves such as the tricuspid valve, aortic valve, pulmonary valve, etc, as well as other valves in the body such as venous valves.
Prosthetic Valve. Prosthetic valves have been surgically implanted in the heart as a treatment for mitral regurgitation. Some of these valves have been valves harvested from animals such as porcine valves, and others have been prosthetic mechanical valves with or without a tissue covering. More recently, minimally invasive catheter technology has been used to deliver prosthetic valves to the heart. These valves typically include an anchor for securing the valve to the patient's heart, and a valve mechanism, either a mechanical valve, a valve with animal tissue, or combinations thereof. The prosthetic valve once implanted, takes over for the malfunctioning native valve, thereby reducing or eliminating valvar insufficiency. While some of these valves appear promising, there still is a need for improved valves. Positioning and anchoring the prosthetic valve in the native anatomy remains a challenge. The following specification discloses exemplary embodiments of a prosthetic valve, a delivery system for the prosthetic valve, and methods of delivering the valve that overcome some of the challenges associated with existing prosthetic valves.
Atrial region 606 has a skirt 616 which includes a plurality of interconnected struts that form a series of peaks and valleys. In this region, the struts are skewed relative to one another and thus the resulting cell pattern has an enlarged end and the opposite end tapers to a smaller end. In preferred embodiments, the anterior portion of the atrial skirt does not have a flanged region like the posterior portion, thus the anterior portion 602 of the atrial region may have shorter struts than the posterior region 604. Thus the peaks and valleys in the anterior portion are axially offset from those in the remaining posterior portion of the atrial region. This may be advantageous as it prevents the struts in the anterior portion of the atrial skirt from protruding upwards potentially impinging against the left atrium and causing perforations. Additionally, the shortened struts and offset peaks and valleys form an alignment element 614 that can assist the physician with visualization of delivery of the prosthetic valve to the mitral valve and also with alignment of the prosthetic valve prior to expansion of the prosthetic valve. Optional radiopaque markers 614a are disposed on either side of the offset peaks and valleys and further help with visualization during implantation of the valve. The atrial region preferably self-expands to either a cylindrical shape, or it may have a D-shaped cross-section where the anterior portion 602 is substantially flat, and the posterior portion 604 is cylindrically shaped. This allows the atrial skirt to conform to the anatomy of the native mitral valve, thereby preventing obstruction of the left ventricular outflow tract. Additionally, the atrial skirt may also be formed so that upon expansion, the skirt flares outward and forms a flange that can rest against a superior surface of the mitral valve. The flanged region is preferably along the posterior portion of the atrial skirt, and the anterior portion of the atrial skirt remains flangeless. Or, the flange may extend entirely around the atrial skirt. The atrial region is connected to the adjacent annular region 608 with connecting struts which are preferably linear and substantially parallel to the longitudinal axis of the frame.
The annular region 608 is also comprised of a plurality of axially oriented and interconnected struts that form peaks and valleys that allow radial expansion. The struts are preferably parallel with one another and parallel with the longitudinal axis of the frame. The annular region may also be self-expanding and expand into a cylindrical shape, or more preferably the annular region may expand to have a D-shaped cross-section as described above with respect to the atrial region. Thus, the annular region may similarly have a flat anterior portion, and a cylindrically shaped posterior portion. Upon delivery, the annular region is aligned with and expanded into engagement with the mitral valve annulus. Connector struts join the annular region with the ventricular region 610.
The ventricular region 610 also includes a plurality of interconnected struts that form peaks and valleys. Additionally, the struts in the ventricular region form the leaflet commissures 613 which are covered with fabric, pericardial tissue, or other materials to form the prosthetic valve leaflets. Holes in the commissures allow suture to be attached thereto. Struts in the ventricular region also form a ventricular skirt 628 which expands outward to engage the anterior and posterior mitral valve leaflets, and struts in the ventricular region also form the anterior tabs 624 and the posterior tab 630. The anterior tabs are designed to capture the anterior mitral valve leaflet between an inner surface of the anterior tab and outer surface of the ventricular skirt. Any adjacent chordae tendineae may also be captured therebetween. Also, the tip of the anterior tab engages the fibrous trigone on an anterior portion of the mitral valve, one on the left and one on the right side. The posterior tab similarly captures the posterior mitral valve leaflet between an inner surface of the posterior tab and an outer surface of the ventricular skirt, along with any adjacent chordae tendineae. This will be described in more detail below.
By controlling strut length or axial position of the anterior or posterior tabs along the frame, deployment of the tabs may be controlled. Thus in this exemplary embodiment, because the length of the struts in the anterior tabs and posterior tabs 624, 630 as well as their relative position along the frame are the same as one another, when a constraining sheath is retracted away from the tabs, the anterior and posterior tabs will partially spring outward together. As the constraining sheath is further retracted, the remainder of the anterior tabs will self-expand radially outward. Further retraction of the constraining sheath then allows the remainder of the posterior tab to finish its radial expansion, and finally the ventricular skirt will radially expand outward. While strut lengths and axial position of the posterior tab and the ventricular skirt are similar, internal struts connect the ventricular skirt with the commissures, and this delays expansion of the ventricular skirt slightly, thus the posterior tab finishes expansion before the ventricular skirt. Using this sequence of deploying the prosthetic valve may allow the valve to be more accurately delivered and also more securely anchored into position.
Suture holes 621 are disposed along the struts of the annular region as well as the ventricular region to allow attachment of a cover such as pericardium or a polymer such as Dacron or ePTFE, or another biocompatible material. The suture holes may also be disposed along any other part of the frame. Barbs 623 are disposed along the ventricular skirt 628 to help anchor the prosthetic valve to adjacent tissue. Commissure tabs or tabs 612 are disposed on the tips of the commissures 613 and may be used to releasably couple the commissures with a delivery system as will be described below. This allows the frame to expand first, and then the commissures may be released from the delivery system afterwards. One of skill in the art will appreciate that a number of strut geometries may be used, and additionally that strut dimensions such as length, width, thickness, etc. may be adjusted in order to provide the prosthesis with the desired mechanical properties such as stiffness, radial crush strength, commissure deflection, etc. Therefore, the illustrated geometry is not intended to be limiting.
The frame may be formed by electrical discharge machining (EDM), laser cutting, photochemical etching, or other techniques known in the art. Hypodermic tubing or flat sheets may be used to form the frame. Once the frame has been cut and formed into a cylinder (if required), it may be radially expanded into a desired geometry and heat treated using known processes to set the shape. Thus, the prosthetic valve may be loaded onto a delivery catheter in a collapsed configuration and constrained in the collapsed configuration with a constraining sheath. Removal of the constraining sheath will allow the prosthesis to self-expand into its unbiased pre-set shape. In other embodiments, an expandable member such as a balloon may be used to radially expand the prosthesis into its preferred expanded configuration by plastic deformation.
Atrial region 706 has a skirt 716 which includes a plurality of interconnected struts that form a series of peaks and valleys. In this region, the struts are skewed relative to one another and thus the resulting cell pattern has an enlarged end and the opposite end tapers to a smaller end. An anterior portion 702 of the atrial region has shorter struts than the posterior region 704. Thus the peaks and valleys in the anterior portion are axially offset from those in the remaining posterior portion of the atrial region. This allows creation of an alignment element 714 to help the physician deliver the prosthetic valve to the mitral valve and align the prosthetic valve prior to expansion of the prosthetic valve. Other aspects of the atrial region 706 are similar to those of the atrial region 606 in
The annular region 708 is also comprised of a plurality of axially oriented and interconnected struts that form peaks and valleys that allow radial expansion. The struts are preferably parallel with one another and parallel with the longitudinal axis of the frame. The annular region may also be self-expanding and expand into a cylindrical shape, or more preferably the annular region may expand to have a D-shaped cross-section as described above with respect to the atrial region. Thus, the annular region may similarly have a flat anterior portion, and a cylindrically shaped posterior portion. Upon delivery, the annular region is aligned with and expanded into engagement with the mitral valve annulus. Connector struts join the annular region with the ventricular region 710.
The ventricular region 710 also includes a plurality of interconnected struts that form peaks and valleys. Additionally, the struts in the ventricular region form the leaflet commissures 713 which are covered with fabric, pericardial tissue, or other materials to form the prosthetic valve leaflets. Holes in the commissures allow suture to be attached thereto. Struts in the ventricular region also form a ventricular skirt 728 which expands outward to engage the anterior and posterior mitral valve leaflets, and struts in the ventricular region also form the anterior tabs 724 and the posterior tab 730. The anterior tabs are designed to capture the anterior mitral valve leaflet between an inner surface of the anterior tab and outer surface of the ventricular skirt. Any adjacent chordae tendineae may also be captured therebetween. Also, the tip of the anterior tab engages the fibrous trigone on an anterior portion of the mitral valve, one on the left and one on the right side. The posterior tab similar captures the posterior mitral valve leaflet between an inner surface of the posterior tab and an outer surface of the ventricular skirt, along with any adjacent chordae tendineae. This will be described in more detail below.
By controlling strut length or axial position of the anterior or posterior tabs along the frame, deployment of the tabs may be controlled. Thus in this exemplary embodiment, because the length of the struts in the anterior tabs and posterior tabs 724, 730 as well as their relative position along the frame are the same as one another, when a constraining sheath is retracted away from the tabs, the anterior and posterior tabs will partially spring outward together. As the constraining sheath is further retracted, the remainder of the anterior tabs will self-expand radially outward because they are the shortest relative to the struts in the ventricular skirt and the posterior tab. Further retraction of the constraining sheath then allows the ventricular skirt to radially expand, and finally further retraction of the sheath allows the remainder of the posterior tab to finish its radial expansion. Using this sequence of deploying the prosthetic valve may allow the valve to be more accurately delivered and also more securely anchored into position.
Suture holes 721 are disposed along the struts of the annular region as well as the ventricular region to allow attachment of a cover such as pericardium or a polymer such as Dacron or ePTFE. The suture holes may also be disposed along any other part of the frame. Barbs 723 are disposed along the ventricular skirt 728 to help anchor the prosthetic valve to adjacent tissue. Commissure tabs or tabs 712 are disposed on the tips of the commissures 713 and may be used to releasably couple the commissures with a delivery system as will be described below. This allows the frame to expand first, and then the commissures may be released from the delivery system afterwards. One of skill in the art will appreciate that a number of strut geometries may be used, and additionally that strut dimensions such as length, width, thickness, etc. may be adjusted in order to provide the prosthesis with the desired mechanical properties such as stiffness, radial crush strength, commissure deflection, etc. Therefore, the illustrated geometry is not intended to be limiting. The frame may be formed similarly as described above with respect to
Atrial region 806 has a skirt 816 which includes a plurality of interconnected struts that form a series of peaks and valleys. In this region, the struts are skewed relative to one another and thus the resulting cell pattern has an enlarged end and the opposite end tapers to a smaller end. An anterior portion 802 of the atrial region has shorter struts than the posterior region 804. Thus the peaks and valleys in the anterior portion are axially offset from those in the remaining posterior portion of the atrial region. This allows creation of an alignment element 814 to help the physician deliver the prosthetic valve to the mitral valve and align the prosthetic valve prior to expansion of the prosthetic valve. Other aspects of the atrial region 806 are similar to those of the atrial region 606 in
The annular region 808 is also comprised of a plurality of axially oriented and interconnected struts that form peaks and valleys that allow radial expansion. The struts are preferably parallel with one another and parallel with the longitudinal axis of the frame. The annular region may also be self-expanding and expand into a cylindrical shape, or more preferably the annular region may expand to have a D-shaped cross-section as described above with respect to the atrial region. Thus, the annular region may similarly have a flat anterior portion, and a cylindrically shaped posterior portion. Upon delivery, the annular region is aligned with and expanded into engagement with the mitral valve annulus. Connector struts join the annular region with the ventricular region 810.
The ventricular region 810 also includes a plurality of interconnected struts that form peaks and valleys. Additionally, the struts in the ventricular region form the leaflet commissures 813 which are covered with fabric, pericardial tissue, or other materials to form the prosthetic valve leaflets. Holes in the commissures allow suture to be attached thereto. Struts in the ventricular region also form a ventricular skirt 828 which expands outward to engage the anterior and posterior mitral valve leaflets, and struts in the ventricular region also form the anterior tabs 824 and the posterior tab 830. The anterior tabs are designed to capture the anterior mitral valve leaflet between an inner surface of the anterior tab and outer surface of the ventricular skirt. Any adjacent chordae tendineae may also be captured therebetween. Also, the tip of the anterior tab engages the fibrous trigone on an anterior portion of the mitral valve, one on the left and one on the right side. The posterior tab similarly captures the posterior mitral valve leaflet between an inner surface of the posterior tab and an outer surface of the ventricular skirt, along with any adjacent chordae tendineae. This will be described in more detail below. The posterior tab is similar to the posterior tabs described above in
By controlling strut length or axial position of the anterior or posterior tabs along the frame, deployment of the tabs may be controlled. Thus in this exemplary embodiment, because the length of the struts in the anterior tabs and posterior tabs 824, 830 as well as their relative position along the frame are the same as one another, when a constraining sheath is retracted away from the tabs, the anterior and posterior tabs will partially spring outward together. As the constraining sheath is further retracted, the remainder of the anterior tabs will self-expand radially outward because they are the shortest relative to the struts in the ventricular skirt and the posterior tab. Further retraction of the constraining sheath then allows the remainder of the posterior tab to finish self-expanding, followed by self-expansion of the ventricular skirt. Using this sequence of deploying the prosthetic valve may allow the valve to be more accurately delivered and also more securely anchored into position.
Suture holes 821 are disposed along the struts of the annular region as well as the ventricular region to allow attachment of a cover such as pericardium or a polymer such as Dacron or ePTFE. The suture holes may also be disposed along any other part of the frame. Barbs 823 are disposed along the ventricular skirt 828 to help anchor the prosthetic valve to adjacent tissue. Commissure tabs or tabs 812 are disposed on the tips of the commissures 813 and may be used to releasably couple the commissures with a delivery system as will be described below. This allows the frame to expand first, and then the commissures may be released from the delivery system afterwards. One of skill in the art will appreciate that a number of strut geometries may be used, and additionally strut dimensions such as length, width, thickness, etc. may be adjusted in order to provide the prosthesis with the desired mechanical properties such as stiffness, radial crush strength, commissure deflection, etc. Therefore, the illustrated geometry is not intended to be limiting. The frame may be formed similarly as described above.
The frame also includes the annular region 910 and ventricular skirt 912. Anterior tabs 904 (only one visible in this view) is fully expanded such that a space exists between the inner surface of the anterior tab and an outer surface of the ventricular skirt. This allows the anterior leaflet and adjacent chordae to be captured therebetween. Similarly, the posterior tab 902 is also fully deployed, with a similar space between the inner surface of the posterior tab 902 and an outer surface of the ventricular skirt. This allows the posterior leaflet and adjacent chordae tendineae to be captured therebetween. The commissure posts 908 are also visible and are disposed in the inner channel formed by the frame. The commissure posts are used to form the prosthetic mitral valve leaflets. The overall shape of the expanded frame is D-shaped, with the anterior portion flat and the posterior portion cylindrically shaped.
Anti-Pivoting Mechanism
As discussed above, preferred embodiments of the device anchor the prosthetic valve to the anterior and posterior valve leaflets.
When the posterior tab fails to anchor the prosthetic valve to the posterior leaflet, the prosthetic valve will only be anchored with the anterior tabs and therefore may pivot or rotate counter-clockwise, or upward into the left atrium as seen in
Delivery System.
Any of the prosthetic cardiac valves disclosed herein may be carried by delivery system 1100. The atrial skirt, annular skirt, anterior tabs, posterior tab and ventricular skirt are loaded over the bell catheter shaft and disposed under the outer sheath catheter shaft 1102. The ventricular skirt is loaded proximally so that it is closest to the handle 1112 and the atrial skirt is loaded most distally so it is closest to the tip 1110. Therefore, retraction of outer sheath catheter shaft 1102 plays a significant part in controlling deployment of the prosthetic cardiac valve. The atrial skirt therefore expands first when the outer sheath catheter is retracted. The prosthetic valve commissures may be coupled with a hub 1106a on the distal portion of hub catheter 1106 and then the bell catheter shaft is disposed thereover, thereby releasably engaging the commissures with the delivery catheter. Once other portions of the prosthetic cardiac valve have expanded, the commissures may be released.
Delivery Method. A number of methods may be used to deliver a prosthetic cardiac valve to the heart. Exemplary methods of delivering a prosthetic mitral valve may include a transluminal delivery route which may also be a transseptal technique which crosses the septum between the right and left sides of the heart, or in more preferred embodiments, a transapical route may be used such as illustrated in
As the outer sheath 1206 continues to be proximally retracted, the annular region of the prosthetic cardiac valve self-expands next into engagement with the valve annulus. The annular region also preferably has the D-shaped geometry, although it may also be cylindrical or have other geometries to match the native anatomy. In
In
Further actuation of the delivery device now retracts the outer sheath 1206 and the bell catheter shaft 1222 so as to remove the constraint from the hub catheter 1224, as illustrated in
As the outer sheath 1306 continues to be proximally retracted, the annular region of the prosthetic cardiac valve self-expands next into engagement with the valve annulus. The annular region also preferably has the D-shaped geometry, although it may also be cylindrical or have other geometries to match the native anatomy. In
In
Further actuation of the delivery device now retracts the outer sheath 1306 and the bell catheter shaft 1322 so as to remove the constraint from the hub catheter 1324, as illustrated in
Deployment of a prosthetic valve that includes a foot element instead of, or in conjunction with the posterior anchor element is similar to the two exemplary methods described above. The major difference being that when the prosthesis does not have a posterior anchor, retraction of the outer sheath allows the foot to self-expand to a profile large enough to minimize or prevent pivoting of the prosthesis upstream into or toward the left atrium. In embodiments having both a posterior anchor and a foot element, retraction of the outer sheath allows both structures to expand. Other aspects of the deployment are generally the same as previously described above.
Tab Covering. In the exemplary embodiments described above, the tabs (anterior trigonal tabs and posterior ventricular tab) are generally narrow and somewhat pointy. The embodiment previously described with respect to
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
The present application is a non-provisional of, and claims the benefit of U.S. Provisional Patent Application No. 61/776,566 filed Mar. 11, 2013; the entire contents of which are incorporated herein by reference. The present application is related to U.S. patent application Ser. No. 13/096,572 filed Apr. 28, 2011; and also related to U.S. patent application Ser. No. 13/679,920 filed Nov. 16, 2012; the entire contents of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3739402 | Kahn et al. | Jun 1973 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4079468 | Liotta et al. | Mar 1978 | A |
4204283 | Bellhouse et al. | May 1980 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4265694 | Boretos et al. | May 1981 | A |
4339831 | Johnson | Jul 1982 | A |
4340977 | Brownlee et al. | Jul 1982 | A |
4470157 | Love | Sep 1984 | A |
4477930 | Totten et al. | Oct 1984 | A |
4490859 | Black et al. | Jan 1985 | A |
4553545 | Maass et al. | Nov 1985 | A |
4655771 | Wallsten et al. | Apr 1987 | A |
4733665 | Palmaz et al. | Mar 1988 | A |
4776337 | Palmaz et al. | Oct 1988 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4865600 | Carpentier et al. | Sep 1989 | A |
4950227 | Savin et al. | Aug 1990 | A |
4994077 | Dobben | Feb 1991 | A |
5067957 | Jervis | Nov 1991 | A |
5197978 | Hess et al. | Mar 1993 | A |
5326371 | Love et al. | Jul 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5344427 | Cottenceau et al. | Sep 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5397355 | Marin et al. | Mar 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5415667 | Frater | May 1995 | A |
5439446 | Barry | Aug 1995 | A |
5474563 | Myler et al. | Dec 1995 | A |
5509930 | Love | Apr 1996 | A |
5545214 | Stevens | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5575818 | Pinchuk | Nov 1996 | A |
5607444 | Lam | Mar 1997 | A |
5607469 | Frey | Mar 1997 | A |
5669919 | Sanders et al. | Sep 1997 | A |
5697382 | Love et al. | Dec 1997 | A |
D390957 | Fontaine | Feb 1998 | S |
5713952 | Vanney et al. | Feb 1998 | A |
5725519 | Penner et al. | Mar 1998 | A |
5769812 | Stevens et al. | Jun 1998 | A |
5807398 | Shaknovich | Sep 1998 | A |
5810873 | Morales | Sep 1998 | A |
5824069 | Lemole et al. | Oct 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5868777 | Lam | Feb 1999 | A |
5868782 | Frantzen | Feb 1999 | A |
5876437 | Vanney et al. | Mar 1999 | A |
5879381 | Moriuchi et al. | Mar 1999 | A |
5902334 | Dwyer et al. | May 1999 | A |
5928281 | Huynh et al. | Jul 1999 | A |
5935108 | Katoh et al. | Aug 1999 | A |
5954764 | Parodi | Sep 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5992000 | Humphrey et al. | Nov 1999 | A |
6004328 | Solar | Dec 1999 | A |
6015431 | Thornton et al. | Jan 2000 | A |
6042606 | Frantzen | Mar 2000 | A |
6053940 | Wijay | Apr 2000 | A |
6074417 | Peredo | Jun 2000 | A |
6086612 | Jansen | Jul 2000 | A |
6113612 | Swanson et al. | Sep 2000 | A |
6113631 | Jansen | Sep 2000 | A |
6132458 | Staehle et al. | Oct 2000 | A |
6152937 | Peterson et al. | Nov 2000 | A |
6159237 | Alt et al. | Dec 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6168616 | Brown, III | Jan 2001 | B1 |
6251093 | Valley et al. | Jun 2001 | B1 |
6280466 | Kugler et al. | Aug 2001 | B1 |
6306141 | Jervis | Oct 2001 | B1 |
6312465 | Griffin et al. | Nov 2001 | B1 |
6336938 | Kavteladze et al. | Jan 2002 | B1 |
6352543 | Cole | Mar 2002 | B1 |
6358277 | Duran | Mar 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440164 | Dimatteo et al. | Aug 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6475237 | Drasler et al. | Nov 2002 | B2 |
6482228 | Norred | Nov 2002 | B1 |
6511491 | Grudem et al. | Jan 2003 | B2 |
6517573 | Pollock et al. | Feb 2003 | B1 |
6527800 | McGuckin, Jr. et al. | Mar 2003 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6602281 | Klein | Aug 2003 | B1 |
6610088 | Gabbay | Aug 2003 | B1 |
6629534 | Goar St et al. | Oct 2003 | B1 |
6641606 | Ouriel et al. | Nov 2003 | B2 |
6652578 | Bailey et al. | Nov 2003 | B2 |
D484979 | Fontaine | Jan 2004 | S |
6676698 | McGuckin et al. | Jan 2004 | B2 |
6682537 | Ouriel et al. | Jan 2004 | B2 |
6695878 | McGuckin et al. | Feb 2004 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6723123 | Kazatchkov et al. | Apr 2004 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6733523 | Shaolian et al. | May 2004 | B2 |
6764505 | Hossainy et al. | Jul 2004 | B1 |
6767362 | Schreck | Jul 2004 | B2 |
6780200 | Jansen | Aug 2004 | B2 |
6790229 | Berreklouw | Sep 2004 | B1 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6814746 | Thompson et al. | Nov 2004 | B2 |
6858034 | Hijlkema et al. | Feb 2005 | B1 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908477 | McGuckin et al. | Jun 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
6926732 | Derus et al. | Aug 2005 | B2 |
6929660 | Ainsworth et al. | Aug 2005 | B1 |
6936058 | Forde et al. | Aug 2005 | B2 |
6979350 | Moll et al. | Dec 2005 | B2 |
7014653 | Ouriel et al. | Mar 2006 | B2 |
7018401 | Hyodoh et al. | Mar 2006 | B1 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7025780 | Gabbay | Apr 2006 | B2 |
7044962 | Elliot et al. | May 2006 | B2 |
7044966 | Svanidze et al. | May 2006 | B2 |
7087088 | Berg et al. | Aug 2006 | B2 |
7147660 | Chobotov et al. | Dec 2006 | B2 |
7147661 | Chobotov et al. | Dec 2006 | B2 |
7147663 | Berg et al. | Dec 2006 | B1 |
7153322 | Alt | Dec 2006 | B2 |
7186265 | Sharkawy et al. | Mar 2007 | B2 |
7198646 | Figulla et al. | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7252682 | Seguin | Aug 2007 | B2 |
D553747 | Fliedner | Oct 2007 | S |
7276078 | Spenser et al. | Oct 2007 | B2 |
7276084 | Yang et al. | Oct 2007 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7381219 | Salahieh et al. | Jun 2008 | B2 |
7393360 | Spenser et al. | Jul 2008 | B2 |
7429269 | Schwammenthal et al. | Sep 2008 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7445631 | Haug et al. | Nov 2008 | B2 |
7455689 | Johnson | Nov 2008 | B2 |
7462191 | Spenser et al. | Dec 2008 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7524330 | Berreklouw | Apr 2009 | B2 |
7527646 | Rahdert et al. | May 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7608114 | Levine et al. | Oct 2009 | B2 |
7615072 | Rust et al. | Nov 2009 | B2 |
7618446 | Andersen et al. | Nov 2009 | B2 |
7618447 | Case et al. | Nov 2009 | B2 |
7628805 | Spenser et al. | Dec 2009 | B2 |
7632298 | Hijlkema et al. | Dec 2009 | B2 |
7637945 | Solem et al. | Dec 2009 | B2 |
7637946 | Solem et al. | Dec 2009 | B2 |
7682390 | Seguin | Mar 2010 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
7712606 | Salahieh et al. | May 2010 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7753949 | Lamphere et al. | Jul 2010 | B2 |
D622387 | Igaki | Aug 2010 | S |
D622388 | Igaki | Aug 2010 | S |
7771463 | Ton et al. | Aug 2010 | B2 |
7771472 | Hendricksen et al. | Aug 2010 | B2 |
7780725 | Haug et al. | Aug 2010 | B2 |
7785360 | Freitag | Aug 2010 | B2 |
7803185 | Gabbay | Sep 2010 | B2 |
7806917 | Xiao | Oct 2010 | B2 |
7806919 | Bloom et al. | Oct 2010 | B2 |
7815589 | Meade et al. | Oct 2010 | B2 |
7815673 | Bloom et al. | Oct 2010 | B2 |
7824443 | Salahieh et al. | Nov 2010 | B2 |
7837727 | Goetz et al. | Nov 2010 | B2 |
7846203 | Cribier | Dec 2010 | B2 |
7871435 | Carpentier et al. | Jan 2011 | B2 |
7892281 | Seguin et al. | Feb 2011 | B2 |
D635261 | Rossi | Mar 2011 | S |
D635262 | Rossi | Mar 2011 | S |
7896915 | Guyenot et al. | Mar 2011 | B2 |
7914569 | Nguyen et al. | Mar 2011 | B2 |
7919112 | Pathak et al. | Apr 2011 | B2 |
7947075 | Goetz et al. | May 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7967853 | Eidenschink et al. | Jun 2011 | B2 |
7972377 | Lane | Jul 2011 | B2 |
7972378 | Tabor et al. | Jul 2011 | B2 |
7981151 | Rowe | Jul 2011 | B2 |
7993392 | Righini et al. | Aug 2011 | B2 |
7993394 | Hariton et al. | Aug 2011 | B2 |
7993395 | Vanermen et al. | Aug 2011 | B2 |
7998196 | Mathison | Aug 2011 | B2 |
8009887 | Ionasec et al. | Aug 2011 | B2 |
8016870 | Chew et al. | Sep 2011 | B2 |
8016877 | Seguin et al. | Sep 2011 | B2 |
8029564 | Johnson et al. | Oct 2011 | B2 |
8048153 | Salahieh et al. | Nov 2011 | B2 |
8052747 | Melnikov et al. | Nov 2011 | B2 |
8052750 | Tuval et al. | Nov 2011 | B2 |
8057538 | Bergin et al. | Nov 2011 | B2 |
8057539 | Ghione et al. | Nov 2011 | B2 |
8057540 | Letac et al. | Nov 2011 | B2 |
8062350 | Gale et al. | Nov 2011 | B2 |
8062359 | Marquez et al. | Nov 2011 | B2 |
8066763 | Alt | Nov 2011 | B2 |
8070799 | Righini et al. | Dec 2011 | B2 |
8070800 | Lock et al. | Dec 2011 | B2 |
8070801 | Cohn | Dec 2011 | B2 |
8070802 | Lamphere et al. | Dec 2011 | B2 |
8075611 | Millwee et al. | Dec 2011 | B2 |
8075615 | Eberhardt et al. | Dec 2011 | B2 |
8078279 | Dennis et al. | Dec 2011 | B2 |
8080054 | Rowe | Dec 2011 | B2 |
8083793 | Lane et al. | Dec 2011 | B2 |
8088158 | Brodeur | Jan 2012 | B2 |
8088404 | Udipi et al. | Jan 2012 | B2 |
8092520 | Quadri | Jan 2012 | B2 |
8100964 | Spence | Jan 2012 | B2 |
8105375 | Navia et al. | Jan 2012 | B2 |
8105377 | Liddicoat | Jan 2012 | B2 |
8109995 | Paniagua et al. | Feb 2012 | B2 |
8109996 | Stacchino et al. | Feb 2012 | B2 |
8114154 | Righini et al. | Feb 2012 | B2 |
8118866 | Herrmann et al. | Feb 2012 | B2 |
8119704 | Wang et al. | Feb 2012 | B2 |
8123801 | Milo | Feb 2012 | B2 |
8128681 | Shoemaker et al. | Mar 2012 | B2 |
8128688 | Ding et al. | Mar 2012 | B2 |
8136218 | Millwee et al. | Mar 2012 | B2 |
8137398 | Tuval et al. | Mar 2012 | B2 |
8137687 | Chen et al. | Mar 2012 | B2 |
8142492 | Forster et al. | Mar 2012 | B2 |
8142494 | Rahdert et al. | Mar 2012 | B2 |
8147504 | Ino et al. | Apr 2012 | B2 |
8155754 | Nygren et al. | Apr 2012 | B2 |
8157852 | Bloom et al. | Apr 2012 | B2 |
8157853 | Laske et al. | Apr 2012 | B2 |
8158187 | Chen et al. | Apr 2012 | B2 |
8163014 | Lane et al. | Apr 2012 | B2 |
8167926 | Hartley et al. | May 2012 | B2 |
8167932 | Bourang et al. | May 2012 | B2 |
8167934 | Styrc et al. | May 2012 | B2 |
8168275 | Lee et al. | May 2012 | B2 |
8170645 | Solar et al. | May 2012 | B2 |
8177799 | Orban, III | May 2012 | B2 |
8177836 | Lee et al. | May 2012 | B2 |
8180428 | Kaiser et al. | May 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8182530 | Huber et al. | May 2012 | B2 |
8182829 | Kleiner et al. | May 2012 | B2 |
8187851 | Shah et al. | May 2012 | B2 |
8195293 | Limousin et al. | Jun 2012 | B2 |
8202529 | Hossainy et al. | Jun 2012 | B2 |
8211169 | Lane et al. | Jul 2012 | B2 |
8216261 | Solem et al. | Jul 2012 | B2 |
8216301 | Bonhoeffer et al. | Jul 2012 | B2 |
8219229 | Cao et al. | Jul 2012 | B2 |
8220121 | Hendriksen et al. | Jul 2012 | B2 |
8221482 | Cottone et al. | Jul 2012 | B2 |
8221493 | Bailey et al. | Jul 2012 | B2 |
8226710 | Nguyen et al. | Jul 2012 | B2 |
8231930 | Castro et al. | Jul 2012 | B2 |
D665079 | Zago | Aug 2012 | S |
D665080 | Zago | Aug 2012 | S |
8236045 | Benichou et al. | Aug 2012 | B2 |
8236241 | Carpentier et al. | Aug 2012 | B2 |
8241274 | Keogh et al. | Aug 2012 | B2 |
8246675 | Zegdi | Aug 2012 | B2 |
8246677 | Ryan | Aug 2012 | B2 |
8246678 | Haug et al. | Aug 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8252052 | Salahieh et al. | Aug 2012 | B2 |
8257724 | Cromack et al. | Sep 2012 | B2 |
8257725 | Cromack et al. | Sep 2012 | B2 |
8262724 | Seguin et al. | Sep 2012 | B2 |
8273118 | Bergin | Sep 2012 | B2 |
8273120 | Dolan | Sep 2012 | B2 |
8276533 | Chambers et al. | Oct 2012 | B2 |
8287584 | Salahieh et al. | Oct 2012 | B2 |
8287591 | Keidar et al. | Oct 2012 | B2 |
8303653 | Bonhoeffer et al. | Nov 2012 | B2 |
8308798 | Pintor et al. | Nov 2012 | B2 |
8313520 | Barbut et al. | Nov 2012 | B2 |
8313525 | Tuval et al. | Nov 2012 | B2 |
8317854 | Ryan et al. | Nov 2012 | B1 |
8323335 | Rowe et al. | Dec 2012 | B2 |
8323336 | Hill et al. | Dec 2012 | B2 |
8337541 | Quadri et al. | Dec 2012 | B2 |
8348995 | Tuval et al. | Jan 2013 | B2 |
8349001 | Mensah et al. | Jan 2013 | B2 |
8349003 | Shu et al. | Jan 2013 | B2 |
8353921 | Schaller et al. | Jan 2013 | B2 |
8353948 | Besselink et al. | Jan 2013 | B2 |
8353953 | Giannetti et al. | Jan 2013 | B2 |
8357387 | Dove et al. | Jan 2013 | B2 |
8361137 | Perouse | Jan 2013 | B2 |
8361537 | Shanley | Jan 2013 | B2 |
8366769 | Huynh et al. | Feb 2013 | B2 |
8377116 | Hsu et al. | Feb 2013 | B2 |
8377499 | Kleiner et al. | Feb 2013 | B2 |
8382816 | Pollock et al. | Feb 2013 | B2 |
RE44075 | Williamson et al. | Mar 2013 | E |
8398707 | Bergin | Mar 2013 | B2 |
8398708 | Meiri et al. | Mar 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8408214 | Spenser | Apr 2013 | B2 |
8409274 | Li et al. | Apr 2013 | B2 |
8414635 | Hyodoh et al. | Apr 2013 | B2 |
8414643 | Tuval et al. | Apr 2013 | B2 |
8414644 | Quadri et al. | Apr 2013 | B2 |
8414645 | Dwork et al. | Apr 2013 | B2 |
8430902 | Bergheim | Apr 2013 | B2 |
8430927 | Bonhoeffer | Apr 2013 | B2 |
8444689 | Zhang | May 2013 | B2 |
8449466 | Duhay et al. | May 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8449625 | Campbell et al. | May 2013 | B2 |
8454684 | Bergin et al. | Jun 2013 | B2 |
8454685 | Hariton et al. | Jun 2013 | B2 |
8460335 | Carpenter | Jun 2013 | B2 |
8460365 | Haverkost et al. | Jun 2013 | B2 |
8460366 | Rowe et al. | Jun 2013 | B2 |
8460370 | Zakay et al. | Jun 2013 | B2 |
8460373 | Fogarty et al. | Jun 2013 | B2 |
8470023 | Eidenschink et al. | Jun 2013 | B2 |
8470024 | Ghione et al. | Jun 2013 | B2 |
8475521 | Suri et al. | Jul 2013 | B2 |
8475522 | Jimenez et al. | Jul 2013 | B2 |
8475523 | Duffy | Jul 2013 | B2 |
8479380 | Malewicz et al. | Jul 2013 | B2 |
8480730 | Maurer et al. | Jul 2013 | B2 |
8480731 | Elizondo et al. | Jul 2013 | B2 |
8486137 | Suri et al. | Jul 2013 | B2 |
8491650 | Wiemeyer et al. | Jul 2013 | B2 |
8500688 | Engel et al. | Aug 2013 | B2 |
8500755 | Ino et al. | Aug 2013 | B2 |
8500798 | Rowe et al. | Aug 2013 | B2 |
8500801 | Eberhardt et al. | Aug 2013 | B2 |
8500802 | Lane et al. | Aug 2013 | B2 |
8506620 | Ryan | Aug 2013 | B2 |
8506625 | Johnson | Aug 2013 | B2 |
8511244 | Holecek et al. | Aug 2013 | B2 |
8512397 | Rolando et al. | Aug 2013 | B2 |
8512398 | Alkhatib | Aug 2013 | B2 |
8512399 | Lafontaine | Aug 2013 | B2 |
8512401 | Murray, III et al. | Aug 2013 | B2 |
8518106 | Duffy et al. | Aug 2013 | B2 |
8518108 | Huynh et al. | Aug 2013 | B2 |
8529621 | Alfieri et al. | Sep 2013 | B2 |
8535368 | Headley et al. | Sep 2013 | B2 |
8539662 | Stacchino et al. | Sep 2013 | B2 |
8545742 | Gada et al. | Oct 2013 | B2 |
8551162 | Fogarty et al. | Oct 2013 | B2 |
8562663 | Mearns et al. | Oct 2013 | B2 |
8562672 | Bonhoeffer et al. | Oct 2013 | B2 |
8562673 | Yeung et al. | Oct 2013 | B2 |
8565872 | Pederson | Oct 2013 | B2 |
8568472 | Marchand et al. | Oct 2013 | B2 |
8579964 | Lane et al. | Nov 2013 | B2 |
8579965 | Bonhoeffer et al. | Nov 2013 | B2 |
8584849 | McCaffrey | Nov 2013 | B2 |
8585749 | Shelso | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8585756 | Bonhoeffer et al. | Nov 2013 | B2 |
8591570 | Revuelta et al. | Nov 2013 | B2 |
8591574 | Lambrecht et al. | Nov 2013 | B2 |
8597348 | Rowe et al. | Dec 2013 | B2 |
8603154 | Strauss et al. | Dec 2013 | B2 |
8603160 | Salahieh et al. | Dec 2013 | B2 |
8603161 | Drews et al. | Dec 2013 | B2 |
8608648 | Banik et al. | Dec 2013 | B2 |
8617236 | Paul et al. | Dec 2013 | B2 |
8623074 | Ryan | Jan 2014 | B2 |
8623080 | Fogarty et al. | Jan 2014 | B2 |
8628566 | Eberhardt et al. | Jan 2014 | B2 |
8632586 | Spenser et al. | Jan 2014 | B2 |
8632608 | Carpentier et al. | Jan 2014 | B2 |
8640521 | Righini et al. | Feb 2014 | B2 |
8641639 | Manstrom et al. | Feb 2014 | B2 |
8647381 | Essinger et al. | Feb 2014 | B2 |
8652201 | Oberti et al. | Feb 2014 | B2 |
8652202 | Alon et al. | Feb 2014 | B2 |
8652203 | Quadri et al. | Feb 2014 | B2 |
8653632 | Pederson et al. | Feb 2014 | B2 |
8663318 | Ho | Mar 2014 | B2 |
8663319 | Ho | Mar 2014 | B2 |
8668730 | McGuckin, Jr. et al. | Mar 2014 | B2 |
8668733 | Salahieh et al. | Mar 2014 | B2 |
8672992 | Orr | Mar 2014 | B2 |
8672997 | Drasler et al. | Mar 2014 | B2 |
8672998 | Lichtenstein et al. | Mar 2014 | B2 |
8672999 | Cali et al. | Mar 2014 | B2 |
8673000 | Tabor et al. | Mar 2014 | B2 |
8679174 | Ottma et al. | Mar 2014 | B2 |
8679404 | Liburd et al. | Mar 2014 | B2 |
8685083 | Perier et al. | Apr 2014 | B2 |
8685086 | Navia et al. | Apr 2014 | B2 |
8690787 | Blomqvist et al. | Apr 2014 | B2 |
8690936 | Nguyen et al. | Apr 2014 | B2 |
8696742 | Pintor et al. | Apr 2014 | B2 |
8707957 | Callister et al. | Apr 2014 | B2 |
8715207 | Righini et al. | May 2014 | B2 |
8715337 | Chuter et al. | May 2014 | B2 |
8715343 | Navia et al. | May 2014 | B2 |
8721707 | Boucher et al. | May 2014 | B2 |
8721708 | Sequin et al. | May 2014 | B2 |
8721713 | Tower et al. | May 2014 | B2 |
8721714 | Kelley | May 2014 | B2 |
8728154 | Alkhatib | May 2014 | B2 |
8728155 | Montorfano et al. | May 2014 | B2 |
8731658 | Hampton et al. | May 2014 | B2 |
8734484 | Ahlberg et al. | May 2014 | B2 |
8740930 | Goodwin | Jun 2014 | B2 |
8740974 | Lambrecht et al. | Jun 2014 | B2 |
8740975 | Yang et al. | Jun 2014 | B2 |
8740976 | Tran et al. | Jun 2014 | B2 |
8747458 | Tuval et al. | Jun 2014 | B2 |
8747459 | Nguyen et al. | Jun 2014 | B2 |
8747460 | Tuval et al. | Jun 2014 | B2 |
8753384 | Leanna | Jun 2014 | B2 |
8758432 | Solem et al. | Jun 2014 | B2 |
8764814 | Solem | Jul 2014 | B2 |
8764820 | Dehdashtian et al. | Jul 2014 | B2 |
8771302 | Woolfson et al. | Jul 2014 | B2 |
8771344 | Tran et al. | Jul 2014 | B2 |
8771345 | Tuval et al. | Jul 2014 | B2 |
8771346 | Tuval et al. | Jul 2014 | B2 |
8777975 | Kashkarov et al. | Jul 2014 | B2 |
8778018 | Iobbi | Jul 2014 | B2 |
8784478 | Tuval et al. | Jul 2014 | B2 |
8784480 | Taylor et al. | Jul 2014 | B2 |
8784481 | Alkhatib et al. | Jul 2014 | B2 |
8790387 | Nguyen et al. | Jul 2014 | B2 |
8790395 | Straubinger et al. | Jul 2014 | B2 |
8790396 | Bergheim et al. | Jul 2014 | B2 |
8791171 | Pacetti et al. | Jul 2014 | B2 |
8795356 | Quadri et al. | Aug 2014 | B2 |
8801776 | House et al. | Aug 2014 | B2 |
8808366 | Braido et al. | Aug 2014 | B2 |
8808370 | Nitzan et al. | Aug 2014 | B2 |
8821569 | Gurskis et al. | Sep 2014 | B2 |
8821570 | Dumontelle et al. | Sep 2014 | B2 |
8828078 | Salahieh et al. | Sep 2014 | B2 |
8828079 | Thielen et al. | Sep 2014 | B2 |
8834561 | Figulla et al. | Sep 2014 | B2 |
8834564 | Tuval et al. | Sep 2014 | B2 |
8840661 | Manasse | Sep 2014 | B2 |
8845718 | Tuval et al. | Sep 2014 | B2 |
8845720 | Conklin | Sep 2014 | B2 |
8852267 | Cattaneo | Oct 2014 | B2 |
8858620 | Salahieh et al. | Oct 2014 | B2 |
8858621 | Oba et al. | Oct 2014 | B2 |
8870936 | Rowe | Oct 2014 | B2 |
8870947 | Shaw | Oct 2014 | B2 |
8870948 | Erzberger et al. | Oct 2014 | B1 |
8876712 | Yee et al. | Nov 2014 | B2 |
8876883 | Rust | Nov 2014 | B2 |
8876893 | Dwork et al. | Nov 2014 | B2 |
8876894 | Tuval et al. | Nov 2014 | B2 |
8876895 | Tuval et al. | Nov 2014 | B2 |
8882831 | Alkhatib | Nov 2014 | B2 |
8894702 | Quadri et al. | Nov 2014 | B2 |
8894703 | Salahieh et al. | Nov 2014 | B2 |
8906081 | Cully et al. | Dec 2014 | B2 |
8911455 | Quadri et al. | Dec 2014 | B2 |
8911844 | Ford | Dec 2014 | B2 |
8926688 | Burkart et al. | Jan 2015 | B2 |
8926693 | Duffy et al. | Jan 2015 | B2 |
8932349 | Jenson et al. | Jan 2015 | B2 |
8940887 | Chatterton et al. | Jan 2015 | B2 |
8945208 | Jimenez et al. | Feb 2015 | B2 |
8945209 | Bonyuet et al. | Feb 2015 | B2 |
8945210 | Cartledge et al. | Feb 2015 | B2 |
8951280 | Cohn et al. | Feb 2015 | B2 |
8951299 | Paul et al. | Feb 2015 | B2 |
8961583 | Hojeibane et al. | Feb 2015 | B2 |
8961589 | Kleiner et al. | Feb 2015 | B2 |
8961593 | Bonhoeffer et al. | Feb 2015 | B2 |
8961595 | Alkhatib | Feb 2015 | B2 |
8968393 | Rothstein | Mar 2015 | B2 |
8968395 | Hauser et al. | Mar 2015 | B2 |
8974524 | Yeung et al. | Mar 2015 | B2 |
8979922 | Thambar et al. | Mar 2015 | B2 |
8986372 | Murry, III et al. | Mar 2015 | B2 |
8986713 | Cleek et al. | Mar 2015 | B2 |
8992608 | Salahieh et al. | Mar 2015 | B2 |
8998978 | Wang | Apr 2015 | B2 |
8998979 | Seguin et al. | Apr 2015 | B2 |
8998980 | Shipley et al. | Apr 2015 | B2 |
8998981 | Tuval et al. | Apr 2015 | B2 |
8999369 | Gale et al. | Apr 2015 | B2 |
9005273 | Salahieh et al. | Apr 2015 | B2 |
9005277 | Pintor et al. | Apr 2015 | B2 |
9011521 | Haug et al. | Apr 2015 | B2 |
9011523 | Seguin | Apr 2015 | B2 |
9011524 | Eberhardt | Apr 2015 | B2 |
9011528 | Ryan et al. | Apr 2015 | B2 |
9023100 | Quadri et al. | May 2015 | B2 |
9028545 | Taylor | May 2015 | B2 |
9029418 | Dove et al. | May 2015 | B2 |
9034033 | McLean et al. | May 2015 | B2 |
9055937 | Rowe et al. | Jun 2015 | B2 |
9078749 | Lutter et al. | Jul 2015 | B2 |
9078751 | Naor | Jul 2015 | B2 |
9084676 | Chau et al. | Jul 2015 | B2 |
9125738 | Figulla et al. | Sep 2015 | B2 |
9138312 | Tuval et al. | Sep 2015 | B2 |
9161834 | Taylor et al. | Oct 2015 | B2 |
D755384 | Pesce et al. | May 2016 | S |
9333074 | Quadri et al. | May 2016 | B2 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010047180 | Grudem et al. | Nov 2001 | A1 |
20010047200 | White et al. | Nov 2001 | A1 |
20020016623 | Kula et al. | Feb 2002 | A1 |
20020022853 | Swanson et al. | Feb 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020045929 | Diaz | Apr 2002 | A1 |
20020052644 | Shaolian et al. | May 2002 | A1 |
20020055772 | McGuckin et al. | May 2002 | A1 |
20020111619 | Keast et al. | Aug 2002 | A1 |
20020183827 | Derus et al. | Dec 2002 | A1 |
20030040792 | Gabbay | Feb 2003 | A1 |
20030105517 | White et al. | Jun 2003 | A1 |
20030114913 | Spenser et al. | Jun 2003 | A1 |
20030120263 | Ouriel et al. | Jun 2003 | A1 |
20030120330 | Ouriel et al. | Jun 2003 | A1 |
20030120333 | Ouriel et al. | Jun 2003 | A1 |
20030125797 | Chobotov et al. | Jul 2003 | A1 |
20030130729 | Paniagua et al. | Jul 2003 | A1 |
20030176914 | Rabkin et al. | Sep 2003 | A1 |
20030199971 | Tower et al. | Oct 2003 | A1 |
20030220683 | Minasian et al. | Nov 2003 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040087900 | Thompson et al. | May 2004 | A1 |
20040093058 | Cottone et al. | May 2004 | A1 |
20040093060 | Seguin et al. | May 2004 | A1 |
20040102842 | Jansen | May 2004 | A1 |
20040117009 | Cali et al. | Jun 2004 | A1 |
20040133273 | Cox | Jul 2004 | A1 |
20040181238 | Zarbatany et al. | Sep 2004 | A1 |
20040186561 | McGuckin et al. | Sep 2004 | A1 |
20040193261 | Berreklouw | Sep 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040210307 | Khairkhahan | Oct 2004 | A1 |
20040215325 | Penn et al. | Oct 2004 | A1 |
20040225353 | McGuckin et al. | Nov 2004 | A1 |
20040236411 | Sarac et al. | Nov 2004 | A1 |
20040243230 | Navia et al. | Dec 2004 | A1 |
20040249433 | Freitag | Dec 2004 | A1 |
20040260390 | Sarac et al. | Dec 2004 | A1 |
20050033398 | Seguin | Feb 2005 | A1 |
20050038470 | Van Der Burg et al. | Feb 2005 | A1 |
20050075727 | Wheatley | Apr 2005 | A1 |
20050090887 | Pryor | Apr 2005 | A1 |
20050096738 | Cali et al. | May 2005 | A1 |
20050107872 | Mensah et al. | May 2005 | A1 |
20050125020 | Meade et al. | Jun 2005 | A1 |
20050137682 | Justino | Jun 2005 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137693 | Haug et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137701 | Salahieh et al. | Jun 2005 | A1 |
20050154444 | Quadri | Jul 2005 | A1 |
20050159811 | Lane | Jul 2005 | A1 |
20050182483 | Osborne et al. | Aug 2005 | A1 |
20050182486 | Gabbay | Aug 2005 | A1 |
20050203616 | Cribier | Sep 2005 | A1 |
20050216079 | MaCoviak | Sep 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20050283231 | Haug et al. | Dec 2005 | A1 |
20060020247 | Kagan et al. | Jan 2006 | A1 |
20060020327 | Lashinski et al. | Jan 2006 | A1 |
20060020334 | Lashinski et al. | Jan 2006 | A1 |
20060052802 | Sterman et al. | Mar 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060064120 | Levine et al. | Mar 2006 | A1 |
20060095115 | Bladillah et al. | May 2006 | A1 |
20060106454 | Osborne et al. | May 2006 | A1 |
20060116625 | Renati et al. | Jun 2006 | A1 |
20060129235 | Seguin et al. | Jun 2006 | A1 |
20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
20060161265 | Levine et al. | Jul 2006 | A1 |
20060173537 | Yang et al. | Aug 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060212110 | Osborne et al. | Sep 2006 | A1 |
20060224232 | Chobotov | Oct 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060253191 | Salahieh et al. | Nov 2006 | A1 |
20060259135 | Navia et al. | Nov 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20060287717 | Rowe et al. | Dec 2006 | A1 |
20060287719 | Rowe et al. | Dec 2006 | A1 |
20060293698 | Douk | Dec 2006 | A1 |
20060293745 | Carpentier et al. | Dec 2006 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070016286 | Herrmann et al. | Jan 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070050020 | Spence | Mar 2007 | A1 |
20070050021 | Johnson | Mar 2007 | A1 |
20070067016 | Jung | Mar 2007 | A1 |
20070100432 | Case et al. | May 2007 | A1 |
20070118206 | Colgan et al. | May 2007 | A1 |
20070118207 | Amplatz et al. | May 2007 | A1 |
20070129794 | Realyvasquez | Jun 2007 | A1 |
20070142906 | Figulla et al. | Jun 2007 | A1 |
20070162107 | Haug et al. | Jul 2007 | A1 |
20070185559 | Shelso | Aug 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070219620 | Eells et al. | Sep 2007 | A1 |
20070233228 | Eberhardt et al. | Oct 2007 | A1 |
20070250151 | Pereira | Oct 2007 | A1 |
20070255391 | Hojeibane et al. | Nov 2007 | A1 |
20070255394 | Ryan | Nov 2007 | A1 |
20070265656 | Amplatz et al. | Nov 2007 | A1 |
20070270932 | Headley et al. | Nov 2007 | A1 |
20070270937 | Leanna | Nov 2007 | A1 |
20070293940 | Schaeffer et al. | Dec 2007 | A1 |
20080009934 | Schneider et al. | Jan 2008 | A1 |
20080021546 | Patz et al. | Jan 2008 | A1 |
20080071361 | Tuval et al. | Mar 2008 | A1 |
20080071363 | Tuval et al. | Mar 2008 | A1 |
20080071366 | Tuval et al. | Mar 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080082164 | Friedman | Apr 2008 | A1 |
20080082165 | Wilson et al. | Apr 2008 | A1 |
20080082166 | Styrc et al. | Apr 2008 | A1 |
20080087581 | Eisenhut et al. | Apr 2008 | A1 |
20080097571 | Denison et al. | Apr 2008 | A1 |
20080114441 | Rust et al. | May 2008 | A1 |
20080125853 | Bailey et al. | May 2008 | A1 |
20080125859 | Salahieh et al. | May 2008 | A1 |
20080133003 | Seguin et al. | Jun 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080147179 | Cai et al. | Jun 2008 | A1 |
20080147183 | Styrc | Jun 2008 | A1 |
20080154358 | Tansley et al. | Jun 2008 | A1 |
20080161911 | Revuelta et al. | Jul 2008 | A1 |
20080177381 | Navia et al. | Jul 2008 | A1 |
20080183273 | Mesana et al. | Jul 2008 | A1 |
20080208307 | Ben-Muvhar et al. | Aug 2008 | A1 |
20080208328 | Antocci et al. | Aug 2008 | A1 |
20080208332 | Lamphere et al. | Aug 2008 | A1 |
20080221672 | Lamphere et al. | Sep 2008 | A1 |
20080228201 | Zarbatany et al. | Sep 2008 | A1 |
20080228254 | Ryan | Sep 2008 | A1 |
20080243233 | Ben-Muvhar et al. | Oct 2008 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080255660 | Guyenot et al. | Oct 2008 | A1 |
20080255661 | Straubinger et al. | Oct 2008 | A1 |
20080262596 | Xiao | Oct 2008 | A1 |
20080262603 | Giaquinta et al. | Oct 2008 | A1 |
20080269878 | Iobbi | Oct 2008 | A1 |
20080275549 | Rowe | Nov 2008 | A1 |
20080288062 | Andrieu et al. | Nov 2008 | A1 |
20080319526 | Hill et al. | Dec 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090012602 | Quadri | Jan 2009 | A1 |
20090054976 | Tuval et al. | Feb 2009 | A1 |
20090062908 | Bonhoeffer et al. | Mar 2009 | A1 |
20090076531 | Richardson et al. | Mar 2009 | A1 |
20090076585 | Hendriksen et al. | Mar 2009 | A1 |
20090076598 | Salahieh et al. | Mar 2009 | A1 |
20090082844 | Zacharias et al. | Mar 2009 | A1 |
20090082847 | Zacharias et al. | Mar 2009 | A1 |
20090088832 | Chew et al. | Apr 2009 | A1 |
20090112309 | Jaramillo et al. | Apr 2009 | A1 |
20090118744 | Wells et al. | May 2009 | A1 |
20090118824 | Samkov | May 2009 | A1 |
20090118826 | Khaghani | May 2009 | A1 |
20090125096 | Chu et al. | May 2009 | A1 |
20090132035 | Roth et al. | May 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090149946 | Dixon | Jun 2009 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090163934 | Raschdorf, Jr. et al. | Jun 2009 | A1 |
20090171438 | Chuter et al. | Jul 2009 | A1 |
20090171456 | Kveen et al. | Jul 2009 | A1 |
20090177262 | Oberti et al. | Jul 2009 | A1 |
20090182407 | Leanna et al. | Jul 2009 | A1 |
20090182413 | Burkart et al. | Jul 2009 | A1 |
20090188964 | Orlov | Jul 2009 | A1 |
20090192601 | Rafiee et al. | Jul 2009 | A1 |
20090216314 | Quadri | Aug 2009 | A1 |
20090216317 | Cromack et al. | Aug 2009 | A1 |
20090222076 | Figulla et al. | Sep 2009 | A1 |
20090227992 | Nir et al. | Sep 2009 | A1 |
20090234443 | Ottma et al. | Sep 2009 | A1 |
20090248132 | Bloom et al. | Oct 2009 | A1 |
20090248133 | Bloom et al. | Oct 2009 | A1 |
20090258958 | Ford | Oct 2009 | A1 |
20090264989 | Bonhoeffer et al. | Oct 2009 | A1 |
20090264997 | Salahieh et al. | Oct 2009 | A1 |
20090270972 | Lane | Oct 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090281618 | Hill et al. | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20090287296 | Manasse | Nov 2009 | A1 |
20090287299 | Tabor et al. | Nov 2009 | A1 |
20090292350 | Eberhardt et al. | Nov 2009 | A1 |
20090306768 | Quadri | Dec 2009 | A1 |
20090318871 | Zarbatany et al. | Dec 2009 | A1 |
20100004740 | Seguin et al. | Jan 2010 | A1 |
20100036479 | Hill et al. | Feb 2010 | A1 |
20100049306 | House et al. | Feb 2010 | A1 |
20100082089 | Quadri et al. | Apr 2010 | A1 |
20100082094 | Quadri et al. | Apr 2010 | A1 |
20100094411 | Tuval et al. | Apr 2010 | A1 |
20100114299 | Ben et al. | May 2010 | A1 |
20100114305 | Kang et al. | May 2010 | A1 |
20100121461 | Sobrino-Serrano et al. | May 2010 | A1 |
20100161027 | Orr | Jun 2010 | A1 |
20100179633 | Solem et al. | Jul 2010 | A1 |
20100179647 | Carpenter et al. | Jul 2010 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100249894 | Oba et al. | Sep 2010 | A1 |
20100249908 | Chau et al. | Sep 2010 | A1 |
20100256723 | Murray | Oct 2010 | A1 |
20100262157 | Silver et al. | Oct 2010 | A1 |
20100274345 | Rust | Oct 2010 | A1 |
20100280606 | Naor | Nov 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20100305685 | Millwee et al. | Dec 2010 | A1 |
20100312333 | Navia et al. | Dec 2010 | A1 |
20110004296 | Lutter et al. | Jan 2011 | A1 |
20110015731 | Carpentier et al. | Jan 2011 | A1 |
20110022157 | Essinger et al. | Jan 2011 | A1 |
20110022165 | Oba et al. | Jan 2011 | A1 |
20110029067 | McGuckin, Jr. et al. | Feb 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110166644 | Keeble et al. | Jul 2011 | A1 |
20110178597 | Navia et al. | Jul 2011 | A9 |
20110208290 | Straubinger | Aug 2011 | A1 |
20110208297 | Tuval et al. | Aug 2011 | A1 |
20110218619 | Benichou et al. | Sep 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110264196 | Savage et al. | Oct 2011 | A1 |
20110282438 | Drews et al. | Nov 2011 | A1 |
20110301704 | Alfieri et al. | Dec 2011 | A1 |
20110313515 | Quadri et al. | Dec 2011 | A1 |
20110319981 | Hill et al. | Dec 2011 | A1 |
20110319989 | Lane | Dec 2011 | A1 |
20120012487 | Tian et al. | Jan 2012 | A1 |
20120016342 | Brecker | Jan 2012 | A1 |
20120016411 | Tuval | Jan 2012 | A1 |
20120022605 | Jahns et al. | Jan 2012 | A1 |
20120022633 | Olson | Jan 2012 | A1 |
20120022639 | Hacohen et al. | Jan 2012 | A1 |
20120022640 | Gross | Jan 2012 | A1 |
20120022642 | Haug et al. | Jan 2012 | A1 |
20120029627 | Salahieh et al. | Feb 2012 | A1 |
20120035703 | Lutter et al. | Feb 2012 | A1 |
20120035713 | Lutter et al. | Feb 2012 | A1 |
20120041550 | Salahieh et al. | Feb 2012 | A1 |
20120041551 | Spenser et al. | Feb 2012 | A1 |
20120059452 | Boucher et al. | Mar 2012 | A1 |
20120059454 | Millwee et al. | Mar 2012 | A1 |
20120078353 | Quadri et al. | Mar 2012 | A1 |
20120078360 | Rafiee | Mar 2012 | A1 |
20120101571 | Thambar et al. | Apr 2012 | A1 |
20120101572 | Kovalsky et al. | Apr 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120179051 | Pfeiffer et al. | Jul 2012 | A1 |
20120179239 | Quadri | Jul 2012 | A1 |
20120179243 | Yang et al. | Jul 2012 | A1 |
20120185033 | Ryan | Jul 2012 | A1 |
20120215303 | Quadri et al. | Aug 2012 | A1 |
20120259405 | Weber et al. | Oct 2012 | A1 |
20120259409 | Nguyen et al. | Oct 2012 | A1 |
20120271398 | Essinger et al. | Oct 2012 | A1 |
20120283820 | Tseng et al. | Nov 2012 | A1 |
20120283824 | Lutter et al. | Nov 2012 | A1 |
20120290062 | McNamara et al. | Nov 2012 | A1 |
20120296418 | Bonyuet et al. | Nov 2012 | A1 |
20120303116 | Gorman, III et al. | Nov 2012 | A1 |
20120310328 | Olson et al. | Dec 2012 | A1 |
20120323316 | Chau et al. | Dec 2012 | A1 |
20120330409 | Haug et al. | Dec 2012 | A1 |
20130006294 | Kashkarov et al. | Jan 2013 | A1 |
20130018458 | Yohanan et al. | Jan 2013 | A1 |
20130030418 | Taft et al. | Jan 2013 | A1 |
20130030523 | Padala et al. | Jan 2013 | A1 |
20130046378 | Millwee et al. | Feb 2013 | A1 |
20130053949 | Pintor et al. | Feb 2013 | A1 |
20130053950 | Rowe et al. | Feb 2013 | A1 |
20130095264 | Sowinski et al. | Apr 2013 | A1 |
20130096671 | Iobbi | Apr 2013 | A1 |
20130110226 | Gurskis | May 2013 | A1 |
20130110227 | Quadri et al. | May 2013 | A1 |
20130110230 | Solem | May 2013 | A1 |
20130116777 | Pintor et al. | May 2013 | A1 |
20130131788 | Quadri et al. | May 2013 | A1 |
20130131793 | Quadri et al. | May 2013 | A1 |
20130138203 | Quadri et al. | May 2013 | A1 |
20130138207 | Quadri et al. | May 2013 | A1 |
20130144375 | Giasolli et al. | Jun 2013 | A1 |
20130144378 | Quadri et al. | Jun 2013 | A1 |
20130144380 | Quadri et al. | Jun 2013 | A1 |
20130144381 | Quadri et al. | Jun 2013 | A1 |
20130150956 | Yohanan et al. | Jun 2013 | A1 |
20130166024 | Drews et al. | Jun 2013 | A1 |
20130172983 | Clerc et al. | Jul 2013 | A1 |
20130184813 | Quadri et al. | Jul 2013 | A1 |
20130184814 | Huynh et al. | Jul 2013 | A1 |
20130211508 | Lane et al. | Aug 2013 | A1 |
20130236889 | Kishimoto et al. | Sep 2013 | A1 |
20130238087 | Taylor | Sep 2013 | A1 |
20130245615 | Koltz | Sep 2013 | A1 |
20130245736 | Alexander et al. | Sep 2013 | A1 |
20130253635 | Straubinger et al. | Sep 2013 | A1 |
20130253637 | Wang et al. | Sep 2013 | A1 |
20130253639 | Alkhatib | Sep 2013 | A1 |
20130253641 | Lattouf | Sep 2013 | A1 |
20130253642 | Brecker | Sep 2013 | A1 |
20130261737 | Costello | Oct 2013 | A1 |
20130261738 | Clague et al. | Oct 2013 | A1 |
20130268069 | Zakai et al. | Oct 2013 | A1 |
20130289695 | Tian et al. | Oct 2013 | A1 |
20130304200 | McLean et al. | Nov 2013 | A1 |
20130310928 | Morriss et al. | Nov 2013 | A1 |
20130325098 | Desai et al. | Dec 2013 | A1 |
20130325121 | Whatley et al. | Dec 2013 | A1 |
20130331714 | Manstrom et al. | Dec 2013 | A1 |
20130338764 | Thornton et al. | Dec 2013 | A1 |
20130338765 | Braido et al. | Dec 2013 | A1 |
20130345786 | Behan | Dec 2013 | A1 |
20130345803 | Bergheim, III | Dec 2013 | A1 |
20140018912 | Delaloye et al. | Jan 2014 | A1 |
20140031930 | Keidar et al. | Jan 2014 | A1 |
20140039611 | Lane et al. | Feb 2014 | A1 |
20140039612 | Dolan | Feb 2014 | A1 |
20140039614 | Delaloye et al. | Feb 2014 | A1 |
20140044689 | Liu et al. | Feb 2014 | A1 |
20140046219 | Sauter et al. | Feb 2014 | A1 |
20140046427 | Michalak | Feb 2014 | A1 |
20140052237 | Lane et al. | Feb 2014 | A1 |
20140052242 | Revuelta et al. | Feb 2014 | A1 |
20140081393 | Hasenkam et al. | Mar 2014 | A1 |
20140086934 | Shams | Mar 2014 | A1 |
20140088685 | Yevzlin et al. | Mar 2014 | A1 |
20140088694 | Rowe et al. | Mar 2014 | A1 |
20140100420 | Mortier et al. | Apr 2014 | A1 |
20140100651 | Kheradvar et al. | Apr 2014 | A1 |
20140100653 | Savage et al. | Apr 2014 | A1 |
20140107761 | Gale et al. | Apr 2014 | A1 |
20140142694 | Tabor et al. | May 2014 | A1 |
20140155997 | Braido | Jun 2014 | A1 |
20140163668 | Rafiee | Jun 2014 | A1 |
20140172085 | Quadri et al. | Jun 2014 | A1 |
20140172086 | Quadri et al. | Jun 2014 | A1 |
20140186417 | Trollsas et al. | Jul 2014 | A1 |
20140194978 | Seguin et al. | Jul 2014 | A1 |
20140194981 | Menk et al. | Jul 2014 | A1 |
20140194982 | Kovalsky et al. | Jul 2014 | A1 |
20140194983 | Kovalsky et al. | Jul 2014 | A1 |
20140214153 | Ottma et al. | Jul 2014 | A1 |
20140214154 | Nguyen et al. | Jul 2014 | A1 |
20140214155 | Kelley | Jul 2014 | A1 |
20140214160 | Naor | Jul 2014 | A1 |
20140215791 | Soundararajan et al. | Aug 2014 | A1 |
20140221823 | Keogh et al. | Aug 2014 | A1 |
20140222136 | Geist et al. | Aug 2014 | A1 |
20140222139 | Nguyen et al. | Aug 2014 | A1 |
20140222142 | Kovalsky et al. | Aug 2014 | A1 |
20140230515 | Tuval et al. | Aug 2014 | A1 |
20140236288 | Lambrecht et al. | Aug 2014 | A1 |
20140243966 | Garde et al. | Aug 2014 | A1 |
20140249622 | Carmi et al. | Sep 2014 | A1 |
20140256035 | Strasly et al. | Sep 2014 | A1 |
20140257475 | Gross et al. | Sep 2014 | A1 |
20140257476 | Montorfano et al. | Sep 2014 | A1 |
20140277390 | Ratz et al. | Sep 2014 | A1 |
20140277402 | Essinger et al. | Sep 2014 | A1 |
20140277422 | Ratz et al. | Sep 2014 | A1 |
20140277423 | Alkhatib et al. | Sep 2014 | A1 |
20140277427 | Ratz et al. | Sep 2014 | A1 |
20140296973 | Bergheim et al. | Oct 2014 | A1 |
20140296975 | Tegels et al. | Oct 2014 | A1 |
20140303719 | Cox et al. | Oct 2014 | A1 |
20140309728 | Dehdashtian et al. | Oct 2014 | A1 |
20140309731 | Quadri et al. | Oct 2014 | A1 |
20140309732 | Solem | Oct 2014 | A1 |
20140324160 | Benichou et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140336754 | Gurskis et al. | Nov 2014 | A1 |
20140350565 | Yacoby et al. | Nov 2014 | A1 |
20140350666 | Righini | Nov 2014 | A1 |
20140356519 | Hossainy et al. | Dec 2014 | A1 |
20140358223 | Rafiee et al. | Dec 2014 | A1 |
20140364404 | Cleek et al. | Dec 2014 | A1 |
20140364944 | Lutter et al. | Dec 2014 | A1 |
20140370071 | Chen et al. | Dec 2014 | A1 |
20140371845 | Tuval et al. | Dec 2014 | A1 |
20140371847 | Madrid et al. | Dec 2014 | A1 |
20140371848 | Murray, III et al. | Dec 2014 | A1 |
20140379067 | Nguyen et al. | Dec 2014 | A1 |
20140379068 | Thielen et al. | Dec 2014 | A1 |
20140379077 | Tuval et al. | Dec 2014 | A1 |
20150012085 | Salahieh et al. | Jan 2015 | A1 |
20150018938 | Von Segesser et al. | Jan 2015 | A1 |
20150018944 | O'Connell et al. | Jan 2015 | A1 |
20150032153 | Quadri et al. | Jan 2015 | A1 |
20150045881 | Lim | Feb 2015 | A1 |
20150066140 | Quadri et al. | Mar 2015 | A1 |
20150081009 | Quadri et al. | Mar 2015 | A1 |
20150086603 | Hossainy et al. | Mar 2015 | A1 |
20150088252 | Jenson et al. | Mar 2015 | A1 |
20150105856 | Rowe et al. | Apr 2015 | A1 |
20150142103 | Vidlund | May 2015 | A1 |
20150148731 | McNamara et al. | May 2015 | A1 |
20150157458 | Thambar et al. | Jun 2015 | A1 |
20150209137 | Quadri et al. | Jul 2015 | A1 |
20150209141 | Braido et al. | Jul 2015 | A1 |
20150216653 | Freudenthal | Aug 2015 | A1 |
20150238315 | Rabito et al. | Aug 2015 | A1 |
20150305864 | Quadri et al. | Oct 2015 | A1 |
20150328000 | Ratz et al. | Nov 2015 | A1 |
20150342736 | Rabito et al. | Dec 2015 | A1 |
20160038281 | Delaloye et al. | Feb 2016 | A1 |
Number | Date | Country |
---|---|---|
2014231689 | Aug 2015 | AU |
2304325 | Oct 2000 | CA |
2900571 | Sep 2014 | CA |
104203158 | Dec 2014 | CN |
109259895 | Jan 2019 | CN |
3128704 | Feb 1983 | DE |
102006052564 | Dec 2007 | DE |
0657147 | Jun 1995 | EP |
1255510 | Apr 2007 | EP |
1472996 | Sep 2009 | EP |
2967860 | Jan 2016 | EP |
1264471 | Feb 1972 | GB |
1315844 | May 1973 | GB |
2245495 | Jan 1992 | GB |
2398245 | Aug 2004 | GB |
2002540889 | Dec 2002 | JP |
2008541865 | Nov 2008 | JP |
WO-9749355 | Dec 1997 | WO |
WO-0053104 | Sep 2000 | WO |
WO-0061034 | Oct 2000 | WO |
WO-0135861 | May 2001 | WO |
WO-0135870 | May 2001 | WO |
WO-0172239 | Oct 2001 | WO |
WO-0236048 | May 2002 | WO |
WO-03028522 | Apr 2003 | WO |
WO-03092554 | Nov 2003 | WO |
WO-2004014257 | Feb 2004 | WO |
WO-2004014474 | Feb 2004 | WO |
WO-2004058097 | Jul 2004 | WO |
WO-2005011534 | Feb 2005 | WO |
WO-2005041810 | May 2005 | WO |
WO-2005087140 | Sep 2005 | WO |
WO-2006070372 | Jul 2006 | WO |
WO-2006085304 | Aug 2006 | WO |
WO-2006089236 | Aug 2006 | WO |
WO 2006097931 | Sep 2006 | WO |
WO-2006127765 | Nov 2006 | WO |
WO-2007025028 | Mar 2007 | WO |
WO-2007034488 | Mar 2007 | WO |
WO-2007058857 | May 2007 | WO |
WO 2007122459 | Nov 2007 | WO |
WO-2007123658 | Nov 2007 | WO |
WO-2007134290 | Nov 2007 | WO |
WO 2008013915 | Jan 2008 | WO |
WO-2008005535 | Jan 2008 | WO |
WO-2008070797 | Jun 2008 | WO |
WO-2008091515 | Jul 2008 | WO |
WO 2008103722 | Aug 2008 | WO |
WO-2008150529 | Dec 2008 | WO |
WO-2009026563 | Feb 2009 | WO |
WO 2009033469 | Mar 2009 | WO |
WO-2009033469 | Mar 2009 | WO |
WO-2009045331 | Apr 2009 | WO |
WO-2009045338 | Apr 2009 | WO |
WO-2009052188 | Apr 2009 | WO |
WO-2009053497 | Apr 2009 | WO |
WO-2009091509 | Jul 2009 | WO |
WO-2009094500 | Jul 2009 | WO |
WO 2009134701 | Nov 2009 | WO |
WO-2009137359 | Nov 2009 | WO |
WO-2009149462 | Dec 2009 | WO |
WO-2009155561 | Dec 2009 | WO |
WO 2010004546 | Jan 2010 | WO |
WO-2010008549 | Jan 2010 | WO |
WO 2010037141 | Apr 2010 | WO |
WO-2010040009 | Apr 2010 | WO |
WO-2010057262 | May 2010 | WO |
WO-2010098857 | Sep 2010 | WO |
WO-2010138853 | Dec 2010 | WO |
WO-2011025945 | Mar 2011 | WO |
WO-2011109813 | Sep 2011 | WO |
WO 2011137531 | Nov 2011 | WO |
WO-2011137531 | Nov 2011 | WO |
WO-2012035279 | Mar 2012 | WO |
WO-2012162228 | Nov 2012 | WO |
WO 2012177942 | Dec 2012 | WO |
WO-2013021374 | Feb 2013 | WO |
WO-2013120181 | Aug 2013 | WO |
WO-2013120181 | Aug 2013 | WO |
Entry |
---|
US 8,062,357 B2, 11/2011, Salahieh et al. (withdrawn) |
US 8,221,315 B2, 07/2012, Lambrecht et al. (withdrawn) |
Bavaria. CardiAQ Valve Technologies (CVT) discloses successful results of acute in vivo study of its novel transcatheter mitral valve implantation (TMVI) system. Enhanced Online News. Sep. 28, 2009. Accessed: Mar. 8, 2012. http://eon.businesswire. com/news/eon/20090928005120/en/CardiAQ-Valve-Technologies/Heart/heart-failure. |
Bavaria. CardiAQ Valve Technologies. TCT Company Overview. Transcatheter Cardiovascular Therapeutics Conference. San Francisco, CA. Sep. 21-25, 2009. |
CardiAQ Valve Technologies. Percutaneous mitral valve replacement. Start-Up. Jun. 2009; 14(6):48-49. |
Carpentier-Edwards. Why compromise in the mitral position? Edwards Lifesciences. 2004. |
Fitzgerald. Tomorrow's technology: percutaneous mitral valve replacement, chordal shortening and beyond. Transcatheter Valve Therapies (TVT) Conference. Seattle, WA. Jun. 7, 2010. |
International search report and written opinion dated Jun. 25, 2014 for PCT/CA2014/000188. |
Mack. Advantages and limitations of surgical mitral valve replacement; lessons for the transcatheter approach. Jun. 7, 2010. Texas Cardiovascular Innovative Ventures (TCIV) Conference. Dallas, TX. Dec. 8, 2010. |
Medical Devices Today. CardiAQ Valve Technologies. Start-Up—Jul. 17, 2009. Accessed: Mar. 8, 2012. http:/www.medicaldevicestoday.com/2009/07/medical-device-start-up-cardiaq-valve-technologies-percutaneous-mitral-valve-replacement.html. |
Ostrovsky. Transcatheter mitral valve implantation technology from CardiAQ. Posted Jan. 15, 2010. Accessed Jun. 27, 2012 from http://medgadget.com/2010/01/transcatheter_mitral_valve_implantation_technology_from_cardiaq.html. |
Ratz. CardiAQ Valve Technologies. Innovations in heartvalve therapy. In3 San Francisco. Jun. 18, 2008. PowerPoint presentation in 19 slides. |
Ruiz. Overview of novel transcatheter valve technologies. Glimpse into the future. New transcatheter mitral valve treatment. Euro PCR. Paris, France. May 27, 2010. |
Al-Attar. Next generation surgical aortic biological prostheses: sutureless valves. European Society of Cardiology. Dec 21, 2011; 10(14):1-3. 0. |
Banai, et al. Tiara: a novel catheter-based mitral valve bioprosthesis: initial experiments and short-term pre-clinical results. J Am Coll Cardiol. Oct. 9, 2012;60(15):1430-1. doi: 10.1016/j.jacc.2012.05.047. Epub Sep. 12, 2012. |
Berreklouw, et al. Sutureless mitral valve replacement with bioprostheses and Nitinol attachment rings: feasibility in acute pig experiments. J Thorac Cardiovasc Surg. Aug. 2011;142(2):390-5.e1. doi: 10.1016/j.jtcvs.2010.12.018. Epub Feb. 4, 2011. |
Boudjemline, et al. Steps toward the percutaneous replacement of atrioventricular valves an experimental study. J Am Coll Cardiol. Jul. 19, 2005;46(2):360-5. |
Brinkman, et al. Transcatheter cardiac valve interventions. Surg Clin North Am. Aug. 2009;89(4):951-66, x. doi: 10.1016/j.suc.2009.06.004. |
CardiAQ Valve Technologies to pursue first-in-man studies of its transcatheter mitral valve system. Cardiac Interventions Today. Jan. 12, 2010. |
Chiam, et al. Percutaneous transcatheter aortic valve implantation: assessing results, judging outcomes, and planning trials: the interventionalist perspective. JACC Cardiovasc Interv. Aug. 2008;1(4):341-50. doi: 10.1016/j.jcin.2008.03.018. |
Condado, et al. Percutaneous treatment of heart valves. Rev Esp Cardiol. Dec. 2006;59(12):1225-31. |
CoreValve USA. An advanced TAVR design. Medtronic.com. Accessed Jan. 27, 2015. |
De Backer, et al. Percutaneous transcatheter mitral valve replacement: an overview of devices in preclinical and early clinical evaluation. Circ Cardiovasc Interv. Jun. 2014;7(3):400-9. doi: 10.1161/CIRCINTERVENTIONS.114.001607. |
Edwards Lifesciences 2005 annual report. Accessed Jan. 27, 2015. |
Fanning, et al. Transcatheter aortic valve implantation (TAVI): valve design and evolution. Int J Cardiol. Oct. 3, 2013;168(3):1822-31. doi: 10.1016/j.ijcard.2013.07.117. Epub Aug. 20, 2013. |
Gillespie, et al. Sutureless mitral valve replacement: initial steps toward a percutaneous procedure. Ann Thorac Surg. Aug. 2013;96(2):670-4. doi: 10.1016/j.athoracsur.2013.02.065. |
Grube, et al. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation. Oct. 10, 2006;114(15):1616-24. Epub Oct. 2, 2006. |
Harmon, et al. Effect of acute myocardial infarction on the angle between the mitral and aortic valve plane. Am J Cardiol. Aug. 1, 1999;84(3):342-4, A8. |
Herrman. Trancatheter mitral valve implantation. Cardiac Interventions Today. Aug./Sep. 2009; 81-85. |
Ionasec, et al. Personalized modeling and assessment of the aortic-mitral coupling from 4D TEE and CT. Med Image Comput Comput Assist Interv. 2009;12(Pt 2):767-75. |
Karimi, et al. Percutaneous Valve Therapies. SIS 2007 Year book. Chapter 11. 11 pages. |
Kumar, et al. Design considerations and quantitative assessment for the development of percutaneous mitral valve stent. Med Eng Phys. Jul. 2014;36(7):882-8. doi: 10.1016/j.medengphy.2014.03.010. Epub Apr. 16, 2014. |
Lauten; et al., “Experimental evaluation of the JenaClip transcatheter aortic valve.”, Sep. 1, 2009, 74(3), 514-9. |
Leon, et al. Transcatheter aortic valve replacement in patients with critical aortic stenosis: rationale, device descriptions, early clinical experiences, and perspectives. Semin Thorac Cardiovasc Surg. 2006 Summer;18(2):165-74. |
Lozonschi, et al. Transapical mitrel valved stent implantation. Ann Thorac Surg. Sep. 2008;86(3):745-8. doi: 10.1016/j.athoracsur.2008.05.039. |
Lutter, et al. Off-pump transapical mitrel valve replacement. Eur J Cardiothorac Surg. Jul. 2009;36(1):124-8; discussion 128. doi: 10.1016/j.ejcts.2009.02.037. Epub Apr. 25, 2009. |
Lutter, et al. Transapical mitrel valve implantation: the Lutter valve. Heart Lung Vessel. 2013;5(4):201-6. |
Ma, et al. Double-crowned valved stents for off-pump mitrel valve replacement. Eur J Cardiothorac Surg. Aug. 2005;28(2):194-8; discussion 198-9. |
Maisano, et al. Mitral transcatheter technologies. Rambam Maimonides Med J. Jul. 25, 2013;4(3):e0015. doi: 10.5041/RMMJ.10115. Print Jul. 2013. |
Navia, et al. Sutureless implantation a expandable mitrel stent-valve prosthesis in acute animal model. TCT728. JACC. Nov. 8, 2011. vol. 58, No. 20 Suppl B. B194. |
Orton. Mitralseal: hybrid trancatheter mitrel valve replacement. Colorado State University. 2011; 311-312. https://www.acvs.org/files/proceedings/2011/data/papers/102.pdf. |
Piazza, et al. Anatomy of the aortic valvar complex and its implications for transcatheter implantation of the aortic valve. Circ Cardiovasc Interv. Aug. 2008;1(1):74-81. doi: 10.1161/CIRCINTERVENTIONS.108.780858. |
Pluth, et al. Aortic and mitrel valve replacement with cloth-covered Braunwald-Cutter prosthesis. A three-year follow-up. Ann Thorac Surg. Sep. 1975;20(3):239-48. |
Preston-Maher, et al. A Technical Review of Minimally Invasive Mitral Valve Replacements. Cardiovasc Eng Technol. 2015;6(2):174-184. Epub Nov. 25, 2014. |
Quadri, et al. CVT is developing a non-surgical apporach to replacing mitral valves that may be the alternative to open-chest surgery. CardiAQ Valve Technologies. May 8, 2009. |
Ribiero, et al. Balloon-expandable prostheses for transcatheter aortic valve replacement. Prog Cardiovasc Dis. May-Jun. 2014;56(6):583-95. doi: 10.1016/j.pcad.2014.02.001. Epub Mar. 1, 2014. |
Seidel, et al. A mitrel valve prosthesis and a study of thrombosis on heart valves in dogs. J Surg Res. May 1962;2:168-75. |
Shuto, et al. Percutaneous transvenous Melody valve-in-ring procedure for mitrel valve replacement. J Am Coll Cardiol. Dec. 6, 2011;58(24):2475-80. doi: 10.1016/j.jacc.2011.09.021. |
Sondergaard, et al. First-in-human CardiAQ transcatheter mitrel valve implantation via transapical approach. TCT-811. JACC. Sep. 13, 2014. vol. 64, No. 11 Suppl B. B237. |
Spencer, et al. Surgical treatment of valvular heart disease. Part V. Prosthetic replacement of the mitral valve. American Heart Journal. Oct. 1968; 76(4):576-580. |
Spillner, et al. New sutureless ‘atrial mitral-valve prosthesis’ for minimally invasive mitrel valve therapy. Textile Research Journal. 2010:1-7. |
Tavr. Engager system. Precise Valve positioning. Accessed Jan. 28, 2015. |
The JenaValve—the prosthesis. JenaValve Technology. Accessed Jan. 28, 2015. |
Timek, et al. Aorto-mitral annular dynamics. Ann Thorac Surg. Dec. 2003;76(6):1944-50. |
Tsang, et al. Changes in aortic-mitral coupling with severe aortic stenosis. JACC. Mar. 9, 2010; vol. 55. Issue 1A. |
Veronesi, et al. A study of functional anatomy of aortic-mitral valve coupling using 3D matrix transesophageal echocardiography. Circ Cardiovasc Imaging. Jan. 2009;2(1):24-31. doi: 10.1161/CIRCIMAGING.108.785907. Epub Dec. 2, 2008. |
Vu, et al. Novel sutureless mitrel valve implantation method involving a bayonet insertion and release mechanism: a proof of concept study in pigs. J Thorac Cardiovasc Surg. Apr. 2012;143(4):985-8. doi: 10.1016/j.jtcvs.2012.01.037. Epub Feb. 11, 2012. |
Walther, et al. Transapical approach for sutureless stent-fixed aortic valve implantation: experimental results. Eur J Cardiothorac Surg. May 2006;29(5):703-8. Epub Apr. 5, 2006. |
Webb, et al. Transcatheter aortic valve implantation: the evolution of prostheses, delivery systems and approaches. Arch Cardiovasc Dis. Mar. 2012;105(3):153-9. doi: 10.1016/j.acvd.2012.02.001. Epub Mar. 16, 2012. |
50 Early-to Late-Stage Medical Device Companies Seeking Investment and Partnering Opportunities to Present in 3 Weeks at Investment in Innovation (In3) Medical Device Summit. Businesswire.com. Dated May 27, 2008. 3 pages. |
CardiAQ's Complaint and Jury Demand; U.S. District Court—District of Massachusetts; Case No. 1:14-cv-12405-ADB; CardiAQ Valve, Technologies Inc. v. Neovasc Inc. and Neovasc Tiara Inc.; filed Jun. 6, 2014. 22 pages. |
CardiAQ's First Amended Complaint and Jury Demand; U.S. District Court—District of Massachusetts; Case No. 1:14-cv-12405-ADB; CardiAQ Valve, Technologies Inc. v. Neovasc Inc. and Neovasc Tiara Inc.; filed Aug. 12, 2014. 21 pages. |
CardiAQ's Objection in Patent Vindication Action in regard to EP 2 566 416; Administrative Court of Munich; CardiAQ Valve Technologies, Inc., v. Neovasc Tiara Inc.; filed on Jun. 25, 2014. 22 pages. |
CardiAQ's Second Amended Complaint and Jury Demand; U.S. District Court—District of Massachusetts; Case No. 1:14-cv-12405-ADB; CardiAQ Valve, Technologies Inc. v. Neovasc Inc. and Neovasc Tiara Inc.; filed Jan. 15, 2015. 25 pages. |
CardiAQ Valve Technologies (CVT) Elects Michael Mack, MD, to its Scientific Advisory Board. “CVT's Transcatheter Mitral Valve Implanation (TMVI) platform might be the ‘next big thing’ in the cardiac cath lab.” BusinessWire. Dated Jun. 2, 2009. 4 pages. |
CardiAQ Valve Technologies (“CVT”) to disclose data during ‘EuroPCR 2010’ about the world's first successful in vivo transcatheter delivery of a mitral heart valve implant. Irvine, California, Businesswire.com. Dated May 20, 2010. 2 pages. |
Company Fact Sheet—CardiAQ Valve Technologies. 2009. 1 page. |
Company Overview—CardiAQ Valve Technologies. Dated Jun. 25, 2009 at TVT. 17 pages. |
Court's Memorandum & Order; U.S. District Court—District of Massachusetts; Case No. 1:14-cv-12405-ADB; CardiAQ Valve, Technologies Inc. v. Neovasc Inc. and Neovasc Tiara Inc.; filed Nov. 6, 2014. 14 pages. |
Defendants Neovasc Inc.'s and Neovasc Tiara Inc.'s Answer to Plaintiff's First Amended Complaint; U.S. District Court—District of Massachusetts; Case No. 1:14-cv-12405-ADB; CardiAQ Valve, Technologies Inc. v. Neovasc Inc. and Neovasc Tiara Inc.; filed Nov. 20, 2014. 20 pages. |
Defendants Neovasc Inc.'s and Neovasc Tiara Inc.'s Answer to Plaintiff's Second Amended Complaint; U.S. District Court—District of Massachusetts; Case No. 1:14-cv-12405-ADB; CardiAQ Valve, Technologies Inc. v. Neovasc Inc. and Neovasc Tiara Inc.; filed Jan. 29, 2015. 22 pages. |
European Extended Search Report dated Jan. 30, 2014 for EP Application No. EP 11798780. |
European Extended Search Report dated Feb. 28, 2013 for EP Application No. EP 06827638. |
Exhibits accompanying CardiAQ's Objection in Patent Vindication Action in regard to EP 2 566 416; filed on Jun. 25, 2014. 306 pages. |
Exhibits accompanying Neovasc's Statement of Defense in Patent Vindication Action in regard to EP 2 566 416; filed on Dec. 9, 2014. 67 pages. |
Feldman, et al. Prospects for percutaneous valve therapies. Circulation. Dec. 11, 2007;116(24):2866-77. |
Grube, et al. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol. Jul. 3, 2007;50(1):69-76. Epub Jun. 6, 2007. |
Horvath, et al. Transapical aortic valve replacement under real-time magnetic resonance imaging guidance: experimental results with balloon-expandable and self-expanding stents. Eur J Cardiothorac Surg. Jun. 2011;39(6):822-8. doi: 10.1016/j.ejcts.2010.09.030. Epub Oct. 22, 2010. |
International Search Report and Written Opinion dated Feb. 29, 2012 for PCT/US2011/041306. |
International Search Report and Written Opinion dated Mar. 26, 2008 for PCT/US2007/016855. |
International Search Report and Written Opinion dated Jun. 25, 2008 for PCT/US2006/043526. |
International Search Report and Written Opinion dated Dec. 11, 2009 for PCT/US2009/058893. |
International Search Report and Written Opinion dated Dec. 18, 2009 for PCT/US2009/059299. |
International Search Report and Written Opinion dated Dec. 22, 2010 for PCT/US2010/031313. |
Kronemyer. CardiAQ Valve Technologies: Percutaneous Mitral Valve Replacement. Start Up—Windhover Review of Emerging Medical Ventures, vol. 14, No. 6, Jun. 2009, pp. 48-49. |
Lansac, et al. Dynamic balance of the aortomitral junction. J Thorac Cardiovasc Surg. May 2002;123(5):911-8. |
Lauten, et al. Experimental evaluation of the JenaClip transcatheter aortic valve. Catheter Cardiovasc Interv. Sep. 1, 2009;74(3):514-9. doi: 10.1002/ccd.22093. |
Lutter, G et al.: “Transcatheter Mitral Valve Replacement—Early Animal Results,” Universitatsklinikum, Schleswig-Holstein. Aug. 28, 2012. |
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: A Short-term Experience in Swine Model.” Applicant believes this may have been presented on May of 2011 at TVT. 10 pages. |
Masson, et al. Percutaneous treatment of mitral regurgitation. Circ Cardiovasc Interv. Apr. 2009;2(2):140-6. doi: 10.1161/CIRCINTERVENTIONS.108.837781. |
Neovasc corporate presentation, Oct. 2009. 21 pages. Available at http://www.neovasc.com/investors/documents/Neovasc-Corporate-Presentation-October-2009.pdf. |
Neovasc Ostial Products Overview. 1 page. https://web.archive.org/web/20090930050359/https://www.neovasc.com/vascular-products/ostialproducts/default.php (Neovasc website archived as of Sep. 30, 2008). |
Neovasc's Statement of Defense in Patent Vindication Action in regard to EP 2 566 416; Administrative Court of Munich; CardiAQ Valve Technologies, Inc., v. Neovasc Tiara Inc.; filed on Dec. 9, 2014. 39 pages. |
Neovasc Surgical Products: An Operating Division of Neovasc Inc. Dated Apr. 2009. 17 pages. |
Nkomo, et al. Burden of valvular heart diseases: a population-based study. Lancet. Sep. 16, 2006;368(9540):1005-11. |
Ormiston, et al. Size and motion of the mitral valve annulus in man. I. A two-dimensional echocardiographic method and findings in normal subjects. Circulation. Jul. 1981;64(1):113-20. |
Ostrovsky, Gene, “A Trial of Zenith Fenestrated AAA Endovascular Graft Goes on,” medGadget, Aug. 1, 2008, 9 pages. Available at: http://www.medgadget.com/2008/08/a_trial_of zenith_fenestrated_aaa_endovascular_graft_goes_on.html. |
Otto. Clinical practice. Evaluation and management of chronic mitral regurgitation. N Engl J Med. Sep. 6, 2001;345(10):740-6. |
Quadri, Arshad M.D., “Transcatheter Mitral Valve Implantation (TMVI) (An Acute In Vivo Study),” Applicant believes this may have been presented on Sep. 22, 2010 at TCT. 19 pages. |
Ratz, et al. “Any experiences making an expandable stent frame?” Arch-Pub.com, Architecture Forums: Modeling, Multiple forum postings from Feb. 3, 2009 to Feb. 4, 2009, http://www.arch-pub.com/Any-experiences-making-an-expandable-stent-frame_10601513.html. 5 pages. |
Ratz, J. Brent et al., “Fabric, Skin, Cloth expansion . . . best approach'?,” AREA by Autodesk, 3ds Max: Modeling, Forum postings from Feb. 18, 2009 to Feb. 19, 2009, http://forums.autodesk.com/t5/modeling/fabric-skin-cloth-expansion-best-approach/td-p/4062607. 3 pages. |
Ratz, J. Brent et al., “Isolating Interpolation,” Arch-Pub.com, Architecture Forums: Animation and Rigging, Forum postings from Feb. 9, 2009 to Feb. 10, 2009, http://www.arch-pub.com/Isolating-Interpolation_10593153.html. 2 pages. |
Ratz, J. Brent, “In3 Company Overview,” Jun. 24, 2009. 15 pages. |
Ratz, J. Brent, “LSI EMT Spotlight,” May 15, 2009. 21 pages. |
Ross, Renal Ostial Stent System with Progressi-flex Technology, Evasc Medical Systems. 1 page. Applicant requests the Examiner to consider this reference to be prior art as of Jun. 2009. |
Update—CardiAQ Valve Technologies. Presented on Jun. 6, 2010 at TVT. 12 pages. |
Van Mieghem, et al. Anatomy of the mitral valvular complex and its implications for transcatheter interventions for mitral regurgitation. J Am Coll Cardiol. Aug. 17, 2010;56(8):617-26. doi: 10.1016/j.jacc.2010.04.030. |
Yamada, et al. The left ventricular ostium: an anatomic concept relevant to idiopathic ventricular arrhythmias. Circ Arrhythm Electrophysiol. Dec. 2008;1(5):396-404. doi: 10.1161/CIRCEP.108.795948. |
European Search Report dated Oct. 17, 2016 for European Application No. 14764106.2. |
“Australian Application Serial No. 2014231689, First Examination Report daetd Sep. 5, 2018”, 3 pgs. |
“Australian Application Serial No. 2014231689, Response file Dec. 19, 2018 to Examination Report dated Sep. 5, 2018”, 24 pgs. |
“European Application Serial No. 14764106.2, Response filed May 15, 2017 to Extended European Search Report dated Oct. 17, 2016”, 27 pgs. |
“International Application Serial No. PCT/CA2014/000188, International Preliminary Report on Patentability dated Sep. 24, 2015”, 8 pgs. |
“European Application Serial No. 14764106.2, Communication Pursuant to Article 94(3) EPC dated Jun. 19, 2019”, 5 pgs. |
“European Application Serial No. 14764106.2, Response filed Oct. 29, 2019 to Communication Pursuant to Article 94(3) EPC dated Jun. 19, 2019”, 12 pgs. |
Number | Date | Country | |
---|---|---|---|
20140257467 A1 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
61776566 | Mar 2013 | US |